American CareSource (ANCI) 10-K 31 Mar 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 29, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	American CareSource Holdings, Inc.
Document Type	10-K
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		6,714,431
Entity Public Float			$12,786,291
Amendment Flag	FALSE
Entity Central Index Key	1316645
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$1,020,000	$6,207,000
Accounts receivable	4,135,000	1,977,000
Prepaid expenses and other current assets	612,000	357,000
Deferred income taxes	6,000	6,000
Total current assets	5,773,000	8,547,000
Property and equipment, net	4,322,000	1,236,000
Other assets:
Deferred income taxes	12,000	215,000
Deferred loan fees, net	2,666,000
Deferred offering costs	225,000
Other non-current assets	488,000	391,000
Intangible assets, net	1,437,000	640,000
Goodwill	6,182,000
Total other assets	11,010,000	1,246,000
Total assets	21,105,000	11,029,000
LIABILITIES AND STOCKHOLDERS' EQUITY
Due to ancillary network	2,308,000	1,865,000
Accounts payable	762,000	258,000
Accrued liabilities	1,875,000	798,000
Current portion of long-term debt	989,000
Capital lease obligations, current portion	117,000
Total current liabilities	6,954,000	2,921,000
Line of credit	4,716,000
Promissory notes and notes payable	312,000
Capital lease obligations	1,764,000
Warrant derivative liability	3,200,000
Other long-term liabilities	222,000
Total long-term liabilities	10,214,000
Total liabilities	17,168,000	2,921,000
Stockholders' equity:
Preferred stock, $0.01 par value; 10,000 shares authorized, none issued	0	0
Common stock, $0.01 par value; 40,000 shares authorized; 6,713 and 5,713 shares issued and outstanding in 2014 and 2013, respectively	67,000	57,000
Additional paid-in capital	25,731,000	23,149,000
Accumulated deficit	-21,861,000	-15,098,000
Total stockholders' equity	3,937,000	8,108,000
Total liabilities and stockholders' equity	21,105,000	11,029,000
Due to Healthsmart [Member]
LIABILITIES AND STOCKHOLDERS' EQUITY
Due to ancillary network	$903,000

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Per Share data, unless otherwise specified
Preferred stock par value (in Dollars per share)	$0.01	$0.01
Preferred stock, shares authorized	10,000	10,000
Preferred stock, shares issued	0	0
Common stock par value (in Dollars per share)	$0.01	$0.01
Common stock, shares authorized	40,000	40,000
Common stock, shares issued	6,713	5,713
Common stock, shares outstanding	6,713	5,713

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Net revenues:
Ancillary network	$23,146,000	$26,751,000
Urgent and primary care	3,906,000
Total net revenues	27,052,000	26,751,000
Operating expenses:
Ancillary network provider payments	16,241,000	19,762,000
Ancillary network administrative fees	1,127,000	1,083,000
Ancillary network operating costs under Management Services Agreement	903,000
Salaries, wages, benefits and taxes	8,157,000	5,250,000
Professional fees	1,866,000	1,262,000
Other operating expenses	4,044,000	2,381,000
Depreciation and amortization	866,000	795,000
Total operating expenses	33,204,000	30,533,000
Operating loss	-6,152,000	-3,782,000
Other (income) expense:
Interest expense	658,000
(Gain)/loss on disposal of assets	-108,000	5,000
Interest income	-9,000	-27,000
Total other (income) expense	541,000	-22,000
Loss before income taxes	-6,693,000	-3,760,000
Income tax expense	70,000	25,000
Net loss	($6,763,000)	($3,785,000)
Basic and diluted net loss per share (in Dollars per share)	($1.05)	($0.66)
Basic and diluted weighted-average shares outstanding (in Shares)	6,407	5,715

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
In Thousands
Balance at December 31 at Dec. 31, 2012	$57	$22,845	($11,313)	$11,589
Balance at December 31 (in Shares) at Dec. 31, 2012	5,706
Net loss			-3,785	-3,785
Stock-based compensation expense		299		299
Issuance of common stock upon exercise of equity incentive awards (in Shares)	5	5		5
Issuance of common stock upon conversion of restricted stock units net of tax withholdings (in Shares)	2
Balance at December 31 at Dec. 31, 2013	57	23,149	-15,098	8,108
Balance at December 31 (in Shares) at Dec. 31, 2013	5,713			5,713
Net loss			-6,763	-6,763
Stock-based compensation expense		592		592
Issuance of common stock	10	1,990		2,000
Issuance of common stock (in Shares)	1,000
Balance at December 31 at Dec. 31, 2014	$67	$25,731	($21,861)	$3,937
Balance at December 31 (in Shares) at Dec. 31, 2014	6,713			6,713

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	($6,763,000)	($3,785,000)
Non-cash stock-based compensation expense	592,000	299,000
Depreciation and amortization	866,000	795,000
Amortization of deferred loan fees	414,000
Unrealized loss on warrant liability	120,000
Gain on sale of property and equipment	-108,000
Change in deferred rent	42,000
Deferred income taxes	58,000	7,000
Loss on write-off of software development costs		5,000
Changes in operating assets and liabilities, net of effects of acquisitions:
Accounts receivable	-1,528,000	455,000
Prepaid expenses and other assets	42,000	-442,000
Due to ancillary network	443,000	-1,235,000
Accounts payable	403,000	-287,000
Accrued liabilities	482,000
Net cash used in operating activities	-4,034,000	-4,188,000
Cash flows from investing activities:
Net change in other non-current assets	-97,000
Cost of acquisitions	-6,921,000
Additions to property and equipment	-776,000	-315,000
Proceeds from sale of property and equipment	131,000
Net cash used in investing activities	-7,663,000	-315,000
Cash flows from financing activities:
Proceeds from borrowings under line of credit	4,716,000
Principal payments on capital lease obligations	-46,000
Proceeds from issuance of common stock	2,000,000
Notes payable payments	-36,000
Offering costs, paid and deferred	-124,000
Proceeds from exercise of equity incentives		5,000
Net cash provided by financing activities	6,510,000	5,000
Net decrease in cash and cash equivalents	-5,187,000	-4,498,000
Cash and cash equivalents at beginning of period	6,207,000	10,705,000
Cash and cash equivalents at end of period	1,020,000	6,207,000
Cash paid for taxes, net of refunds	38,000	117,000
Cash paid for interest	84,000
Warrants issued as loan guarantee and financing	3,080,000
Fair value of debt issued as consideration in acquisitions	1,297,000
Purchase price due to seller, Stat Medical	268,000
Offering costs, deferred and unpaid	101,000
Receivable for tenant improvement allowance	180,000
Debt issued for property and equipment	40,000
Due to Healthsmart [Member]
Changes in operating assets and liabilities, net of effects of acquisitions:
Due to ancillary network	$903,000

Note_1_Description_of_Business

Note 1 - Description of Business and Change in Business Focus	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block [Abstract]
Business Description and Basis of Presentation [Text Block]	1.  Description of Business and Change in Business Focus
	American CareSource Holdings, Inc. ("the Company", "ACSH", "we", "us", or "our") engages in two lines of business:  our urgent and primary care business and our ancillary network business.  These lines of business are supported through a shared services function.
	Urgent and Primary Care Business
	In May 2014, we announced our entry into the urgent and primary care market. During the remainder of 2014, we, through our wholly-owned subsidiaries, acquired ten urgent and primary care centers located in Georgia (three), Florida (two), Alabama (three) and Virginia (two). See Note 3 - Acquisitions.  These centers offer a wide array of services for non-life-threatening medical conditions.  We strive to improve access to quality medical care by offering extended hours and weekend service and also by accepting patients by appointment or on a walk-in basis.
	Ancillary Network Business
	Our ancillary network business offers cost containment strategies, primarily through the utilization of a comprehensive national network of ancillary healthcare service providers.  Our services are marketed to a number of healthcare companies including third-party administrators, insurance companies, large self-funded organizations, various employer groups, and preferred provider organizations.  We offer payors this solution by:
		·	lowering our payors' ancillary care costs throughout network of high quality, cost effective providers that we have under contract at more favorable terms than they could generally obtain on their own;
		·	providing payors with a comprehensive network of ancillary healthcare service providers that is tailored to each payor's needs and is available to each payor's members for covered services;
		·	providing payors with claims management, reporting, processing and payment services;
		·	performing network/needs analysis to assess the benefits to payors of adding additional/different service providers to the payor-specific provider networks; and
		·	credentialing network service providers for inclusion in the payor-specific provider networks.
	On October 1, 2014, we entered into a management services agreement with HealthSmart Preferred Care II, L.P. ("HealthSmart").
	Ancillary Network Business, Management Services Agreement
	Under the management services agreement, HealthSmart manages our ancillary network business, subject to the supervision of a five-person oversight committee comprised of three members selected by us and two members selected by HealthSmart.  As part of the management arrangement, HealthSmart hired substantially all of our ancillary network business employees, purchased substantially all of our furniture, fixtures and equipment located in our Dallas, Texas office and assumed our lease for that office.  As a result of this arrangement, we no longer employ the workforce of our ancillary network business.  Under the management services agreement, HealthSmart manages and operates our ancillary network business for a monthly fee equal to the sum of (a) 35% of the net profit derived from the operation of our ancillary network business plus (b) 120% of all direct and documented operating expenses and liabilities actually paid during such calendar month by HealthSmart in connection with providing its management services.  For purposes of the fee calculation, the term "net profit" means gross ancillary network business revenue, less the sum of (x) the provider payments and administrative fees and (y) 120% of all direct and documented operating expenses and liabilities actually paid during such calendar month by HealthSmart in connection with providing its management services.  Any remaining net profit accrues to us.  During the term of the agreement, HealthSmart is responsible for the payment of all expenses incurred in providing the management services with respect to our ancillary network business, including personnel salaries and benefits, the cost of supplies and equipment, and rent.  The initial term of the management services agreement is three years, and it renews annually thereafter for one-year terms unless either party gives notice of termination at least 90 days prior to the end of the then-current term.
	At any time between October 1, 2016 and the expiration date of the management services agreement, HealthSmart may purchase, or we may require that HealthSmart purchase, our ancillary network business for a price equal to $6,500,000 less the aggregate sum of net profit received by us since the beginning of the management arrangement, which as of December 31, 2014 was $637,786.  Consummation of the transaction will be subject to the satisfaction of certain material conditions, including approval by our stockholders if our annual gross revenue from our urgent and primary care business does not exceed $40,000,000.  If, for any reason, the sale of our ancillary network business to HealthSmart is not consummated during or at the end of the term of the management services agreement, we expect to then either reassume management of that line of business, or seek to sell that business on the most favorable terms we are able to obtain.

Note_2_Basis_of_Presentation_a

Note 2 - Basis of Presentation and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2.  Basis of Presentation and Significant Accounting Policies
	Basis of Presentation
	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries.  All material intercompany accounts and transactions are eliminated in consolidation.
	Certain amounts in the December 2013 income statement presentation were reclassified to conform to the December 2014 presentation. There is no impact on major classifications or net loss due to these reclassifications.
	Liquidity
	During 2014, we made significant investments in our urgent and primary care business.  We used working capital, proceeds from a private equity offering, bank debt and seller financed debt to consummate five transactions totaling $8,486,000, resulting in our acquisition of ten urgent and primary care centers.   We expanded our shared services function to provide the needed infrastructure to manage our urgent and primary care centers and support the planned growth of this business segment.  As a result of these efforts, losses related to the shared services function, as reported in Note 17, increased by $1,825,000 to $5,360,000, during the year ended December 31, 2014, compared to $3,535,000 during the year ended December 31, 2013.
	Our loss from operations increased by $2,370,000 to $6,152,000 during the year ended December 31, 2014 compared to $3,782,000 during the year ended December 31, 2013.  The increase in our operating loss resulted from expanding our shared services function, costs to build out and enhance our current urgent and primary care centers and the continuing decline in our ancillary network business.  As a result of our operating losses, we used cash in our operations of $4,034,000 and $4,188,000 during the years ended December 31, 2014 and 2013, respectively.  We anticipate we will continue to generate operating losses, and use cash in our operations, during the next 12 months, but have made changes to our business model to improve our operating results.  We believe the management service agreement we entered into with HealthSmart, to manage our ancillary network business, will reduce our operating costs.  We will continue to analyze other strategies to improve our ancillary network operating results. Also, we expect to realize the benefits of economies of scale as we acquire additional urgent and primary care centers.
	Until we generate cash flows from operations, we are dependent on our existing lines of credit and outside capital to fund our operations and additional acquisitions.  Our plans to fund these needs include:
		·	Equity financing through the currently filed Form S-1 Registration Statement to sell additional shares of our common stock.  If the offering is fully subscribed, we will raise an additional $15,000,000 (less applicable fees), plus any proceeds we would receive on account of the over allotment options we granted to underwriters.  We anticipate closing this offering during the second quarter of 2015.
		·	Use of our existing lines of credit, which as of March 30, 2015, collectively have $4,000,000 of borrowing capacity.
		·	If necessary, raising additional financing through additional bank borrowing, additional private or public offerings or support from existing guarantors.
	Significant Accounting Policies
	Segment and Related Information – We use the "management approach" for reporting information about segments. The management approach is based on the way the chief operating decision-maker organizes segments within a company for making operating decisions and assessing performance. We analyzed our products and services, geography, legal structure, management structure and any other factors, and we determined that the business is comprised of two reporting segments: urgent and primary business and ancillary network business.  The five businesses acquired were determined to be individual operating segments which have been aggregated into the urgent and primary business.
	Use of Estimates – The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  We consider our most significant estimates to be the collectability of revenue, payments due to providers (and resulting margin as a percentage of revenue), and valuations related to acquisitions and warrants.  Actual amounts could differ from those estimates.
	Risks and Uncertainties – We operate in industries that are subject to intense competition, government regulation and rapid technological change.  Our operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risks, including risk of business failure.
	Cash and Cash Equivalents – We consider all highly-liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents include amounts in deposit accounts in excess of federally-insured limits.  We have not experienced any losses in such accounts.
	Revenue Recognition in Urgent and Primary Care Business – We have agreements with governmental and other third-party payors that provide for payments to us based on contractual adjustments to our established rates. Net revenue is reported at the time service is rendered at the estimated net realizable amounts, after giving effect to estimated contractual amounts from patients, third-party payors and others, and an estimate for bad debts.
	Contractual adjustments are accrued on an estimated basis in the period the related services are rendered, and adjusted in future periods as final settlements are determined.  We grant credit without collateral to our patients, who consist primarily of local residents insured by third-party payors.   A summary of the basis of reimbursement with major third-party payors is as follows:
	Commercial and HMO – We have entered into agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations. Billing methodologies under these agreements include discounts from established charges and prospectively determined rates.
	Medicare – Services rendered to Medicare program beneficiaries are recorded at prospectively determined rates. These rates vary according to a patient classification system that is based on clinical, diagnostic, and other factors.
	In establishing allowance for bad debts, we consider historical collection experience, the aging of the account, payor classification and patient payment patterns.  We adjust this allowance prospectively.
	Collection of payment for services provided to patients without insurance coverage is done at time of service.
	Revenue Recognition in Ancillary Network Business – We recognize revenue on the services that we provide, which includes (i) providing payor clients with a comprehensive network of ancillary healthcare providers; (ii) providing claims management, reporting, processing and payment services; (iii) providing network/need analysis to assess the benefits to payor clients of adding additional/different service providers to the client-specific provider networks; and (iv) providing credentialing of network service providers for inclusion in the client payor-specific provider networks.  Revenue is recognized when services are delivered, which occurs after processed claims are billed to the payor clients and collections are reasonably assured.  We estimate revenues and costs of revenues using average historical collection rates and average historical margins earned on claims.  Periodically, revenues are adjusted to reflect actual cash collections so that revenues recognized accurately reflect cash collected.
	We record a provision for refunds based on an estimate of historical refund amounts.  Refunds are paid to payors for overpayment on claims, claims paid in error, and claims paid for non-covered services.  In some instances, we will recoup payments made to the ancillary service provider if the claim has been fully resolved.  The evaluation is performed periodically and is based on historical data.  We present revenue net of the provision for refunds on the consolidated statement of operations.
	After careful evaluation of the key gross and net revenue recognition indicators, we have concluded that our circumstances are most consistent with those key indicators that support gross revenue reporting, since we are fulfilling the services of a principal versus an agent.
	Following are the key indicators that support our conclusion that we act as a principal when settling claims for service providers through our contracted service provider network:
		·	The Company is the primary obligor in the arrangement. We have assessed our role as primary obligor as a strong indicator of gross reporting.  We believe that we are the primary obligor in our transactions because we are responsible for providing the services desired by our payor clients.  We have distinct, separately negotiated contractual relationships with our payor clients and with the ancillary healthcare providers in our networks.  We do not negotiate "on behalf of" our payor clients and do not hold ourselves out as the agent of the payor clients when negotiating the terms of our ancillary healthcare service provider agreements.  Our agreements contractually prohibit payor clients and service providers from entering into direct contractual relationships with one another.  The payor clients have no control over the terms of our agreements with the service providers.  In executing transactions, we assume key performance-related risks.  The payor clients hold us responsible for fulfillment, as the provider, of all of the services the payor clients are entitled to under their contracts; payor clients do not look to the service providers for fulfillment.  In addition, we bear the pricing/margin risk as the principal in the transactions.  Because the contracts with the payor clients and service providers are separately negotiated, we have complete discretion in negotiating both the prices we charge our payor clients and the financial terms of our agreements with the service providers.  Because our profit is the spread between the amounts received from the payor clients and the amount paid to the service providers, we bear significant pricing and margin risk.  There is no guaranteed mark-up payable to us on the amount we have contracted.  Thus, we bear the risk that amounts paid to the service provider will be greater than the amounts received from the payor clients, resulting in a loss or negative claim.
		·	The Company has latitude in establishing pricing.  As stated above, we are able to negotiate the price payable to us by our payor clients as well as the price to be paid to each contracted service provider.  This type of pricing latitude indicates that we have the risks and rewards normally attributed to a principal in the transactions.
		·	The Company changes the product or performs part of the services. We provide the benefits associated with the relationships we build with the payor clients and the services providers.  While the parties could deal with each other directly, the payor clients would not have the benefit of our experience and expertise in assembling a comprehensive network of service providers, in claims management, reporting and processing and payment services, in performing network/needs analysis to assess the benefits to payor clients of adding additional/different service providers to the client payor-specific provider networks, and in credentialing network service providers.
		·	The Company has complete discretion in supplier selection. We have complete discretion in supplier selection.  One of the key factors considered by payor clients which engage us is to have the Company undertake the responsibility for identifying, qualifying, contracting with and managing the relationships with the ancillary healthcare service providers.  As part of the contractual arrangement between us and our payor clients, the payors identify their obligations to their respective covered persons and then work with us to determine the types of ancillary healthcare services required in order for the payors to meet their obligations.  We may select the providers and contract with them to provide services at its discretion.
		·	The Company is involved in the determination of product or service specifications. We work with our payor clients to determine the types of ancillary healthcare services required in order for the payors to meet their obligations to their respective covered persons.  In some respects, we are customizing the product through our efforts and ability to assemble a comprehensive network of providers for our payors that is tailored to each payor's specific needs.  In addition, as part of our claims processing and payment services, we work with the payor clients, on the one hand, and the providers, on the other, to set claims review, management and payment specifications.
		·	The supplier (and not the Company) has credit risk. We believe we have some level of credit risk, but that risk is mitigated because we do not remit payment to providers unless and until we have received payment from the relevant payor clients following our processing of a claim.
		·	The amount that the Company earns is not fixed. We do not earn a fixed amount per transaction nor do we realize a per-person per-month charge for our services.
	We have evaluated the other indicators of gross and net revenue recognition, including whether or not we have general inventory risk.  We do not have any general inventory risk, as our business is not related to the manufacture, purchase or delivery of goods and we do not purchase in advance any of the services to be provided by the ancillary healthcare service providers.  While the absence of this risk would be one indicator in support of net revenue reporting, as described in detail above, we have carefully evaluated all of the key gross and net revenue recognition indicators and have concluded that our circumstances are more consistent with those key indicators that support gross revenue reporting.
	If, however, we were to report our ancillary network revenues, net of provider payments rather than on a gross reporting basis, for the years ended December 31, 2014 and 2013, our revenues would have been approximately $6,900,000 and $7,000,000, respectively.
	Ancillary Network Provider Payments – Payments to providers is the largest component of our cost of revenues and it consists of payments for ancillary care services in accordance with contracts negotiated with providers for specific ancillary services, separately from contracts negotiated with our clients.
	Advertising Costs – Advertising costs are expensed as incurred.   Advertising expense for the years ended December 31, 2014 and 2013 was approximately $193,000 and $65,000, respectively.
	Property and Equipment – Property and equipment are recorded at original cost and increased by the cost of any significant improvements subsequent to purchase.  Property and equipment acquired through acquisitions are recorded at their estimated fair market value on the date of acquisition. We expense repairs and maintenance as incurred.  Depreciation and amortization is calculated using the straight-line method over the shorter of the asset's estimated useful life or the term of the lease in the case of leasehold improvements. We capitalize costs associated with software developed for internal use. During 2014 and 2013, we capitalized approximately $177,000 and $303,000 of internally-developed software costs, respectively.
	Amortization of assets acquired under capital leases is included as a component of depreciation and amortization expense.  Amortization is calculated using the straight-line method over the shorter of the useful lives or terms of the underlying lease agreements.
	Deferred Loan Fees – Deferred loan fees related to the issuance of warrants in exchange for debt guarantees by certain directors/shareholders are amortized on a straight-line basis over the term of the debt.
	Deferred Offering Costs – Deferred offering costs represent legal, accounting and other direct costs related to raising capital through a stock offering.  Costs related to our planned offering activities are deferred until completion of the offering, at which time they are reclassified to additional paid-in capital as a reduction of the offering proceeds.  There were no offering costs in connection with our private placement in May 2014. In connection with our planned upcoming offering, approximately $225,000 of offering costs have been deferred.
	Impairment of Long-Lived Assets – Long-lived assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of an asset or group of assets might not be recoverable. We perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would indicate a potential impairment include a significant decline in the observable market value of an asset or a significant change in the extent or manner in which an asset is used. The impairment review includes a comparison of future projected cash flows generated by the asset or group of assets with its associated net carrying value. If the net carrying value of the asset or group of assets exceeds expected cash flows (undiscounted and without interest charges), an impairment loss is recognized to the extent the carrying amount of the asset or asset group exceeds its fair value.
	Goodwill – Goodwill resulted from the acquisitions of urgent and primary care businesses during the year ended December 31, 2014.  See Note 3.  In accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 805, Business Combinations, the purchase method of accounting requires that the excess of the purchase price paid over the estimated fair value of identifiable tangible and intangible net assets of acquired businesses be recorded as goodwill.  In accordance with ASC 350, Intangibles – Goodwill and Other, we are required to test goodwill for impairment annually.  We established October 1 as the date of our annual impairment review.  We determined no impairment existed for the period ended September 30, 2014, and there were no factors identified that indicated impairment existed through December 31, 2014.
	Intangible Assets – Intangible assets are recorded at fair values at the date of acquisition. Our intangible assets have finite useful lives and are amortized over their estimated useful lives. See Note. 9.
	Warrant Derivative Liability – We have issued certain warrants which contain an exercise price adjustment feature in the event we issue additional equity instruments at a price lower than the exercise price of the warrant.  The warrants are described herein as derivative warrants.  We account for these derivative warrants as liabilities. These common stock purchase warrants do not trade in an active securities market.  See Note 13 for methodology used to value warrants.
	We compute the fair value of the warrant liability at each reporting period and the change in the fair value is recorded in the statement of operations. The key component in the value of the warrant liability is our stock price, which is subject to significant fluctuation and is not under our control.   The resulting effect on our net income (loss) is, therefore, subject to significant fluctuation and will continue to be so until the warrants are exercised, amended or expire.  Assuming all other fair value inputs remain constant, we will record non-cash income/expense with changes in our stock price or when the underlying assumptions in calculating warrant value change.
	Research and Development – Research and development costs are expensed as incurred.
	Income Taxes – Income taxes are accounted for under the asset and liability method.  Deferred taxes arise because of different treatment between financial statement accounting and tax accounting, known as "temporary differences".  We record the tax effect of these temporary differences as "deferred tax assets" (generally items that can be used as a tax deduction or credit in the future periods) and "deferred tax liabilities" (generally items that we received a tax deduction for, which have not yet been recorded in the statements of operations). The deferred tax assets and liabilities are measured using enacted tax rules and laws that are expected to be in effect when the temporary differences are expected to be recovered or settled. A valuation allowance is established to reduce deferred tax assets considered to be more-likely-than-not that the deferred tax assets will not be realized.
	ASC 740, Income Taxes, clarifies the accounting for uncertainty in income taxes recognized in the financial statements. ASC 740 provides that a tax benefit from uncertain tax positions may be recognized when it is more-likely-than-not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.  Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. ASC 740 also provides guidance on measurement, de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.  At December 31, 2014, and 2013, we had no uncertain tax positions.
	Stock-Based Compensation – We record all stock-based payments to employees in the consolidated financial statements over the vesting period based on our estimated fair values as of the measurement date of the respective awards.  Additional information about our stock-based payment plan is presented in Note 12.
	Fair Value of Financial Instruments – The carrying amount of accounts receivable, accounts payable and accrued expenses, approximate their estimated fair values due to the short-term maturities of those financial instruments. These financial instruments are considered Level 3 measurements under the fair value hierarchy. The fair values of our promissory notes, notes payable, lines of credit and capital lease obligations approximate carrying value under Level 3 of the fair value hierarchy. The fair value of warrants recorded as derivative liabilities are described in Note 14.
	Recent Accounting Pronouncements – In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 660): Summary and Amendments that Create Revenue from Contracts with Customers (Topic 606) and Other Assets and Deferred Costs-Contracts with Customers (Subtopic 340-40).  The guidance in this update supersedes the revenue recognition requirements in ASC Topic 605, Revenue Recognition, and most industry-specific guidance throughout the industry topics of the codification.  This guidance will be effective for interim and annual periods beginning after December 15, 2016.  We are currently assessing the impact that this guidance will have on our consolidated financial statements.
	In August 2014, the FASB ASU 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The guidance relates to the disclosures around going concern.  The new standard update provides guidance around management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures.  The new guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted. We do not believe the adoption of this guidance will have a material impact on our consolidated financial statements.
	Earnings (Loss) Per Share – Basic earnings (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted-average number of common shares outstanding during the period of computation.  Diluted earnings per share is computed similar to basic earnings per share except that the numerator is adjusted for the change in fair value of the warrant liability (only if dilutive), and the denominator is increased to include the number of dilutive potential common shares outstanding during the period using the treasury stock method.
	The following table summarizes potentially dilutive shares outstanding as of December 31, 2014, which were excluded from the calculation due to being anti-dilutive:
			2014		2013
	Common stock purchase warrants			1,782		22
	Stock options			1,245		750
	Restricted shares of common stock			100		51

Note_3_Acquisitions

Note 3 - Acquisitions	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	3.  Acquisitions
	During the year ended December 31, 2014, we entered into five transactions supporting our entry into the urgent and primary care market.  A summary of the acquisitions is as follows (in thousands):
	Business Acquired	State		Sites			Date of		Purchase Price
							Closing
	CorrectMed	Georgia			2		8-May-14		$	2,649
	Bay Walk-In Clinic	Florida			2		29-Aug-14			2,024
	Mid-South Urgent Care	Alabama			3*		12-Sep-14			1,554
	MedHelp	Georgia			1		31-Oct-14			880
	Stat Medical Care	Virginia			2		31-Dec-14			1,379
	Total								$	8,486
	*At the time of closing of this transaction, the seller had two operating centers; the third center in Springville, Alabama, was under development at time of closing.
	Each of these businesses has been included in our results since the date of closing.  Because we did not engage in the urgent and primary care business until May 2014, our annual operating results are not comparable to prior year periods.
	On May 8, 2014, our wholly-owned subsidiary, ACSH Urgent Care of Georgia, LLC, or ACSH Georgia, purchased from CorrectMed, LLC and other sellers substantially all of the assets and assumed certain liabilities used in the operation of two urgent care centers located in Locust Grove, Georgia and Decatur, Georgia.
	On August 29, 2014, our wholly-owned subsidiary, ACSH Urgent Care of Florida, LLC, or ACSH Florida, purchased from Bay Walk-In Clinic, Inc. and other sellers substantially all the assets used in the operation of two urgent care centers located in Panama City and Panama City Beach, Florida.
	On September 12, 2014, our wholly-owned subsidiary, ACSH Urgent Care Holdings, LLC or ACSH Urgent Care, purchased from Jason C. Junkins, M.D. all of the issued and outstanding shares of common stock of Mid-South Urgent Care, Inc. On the acquisition date, this entity operated two urgent care centers in Rainbow City and Hueytown, Alabama. A third clinic in Springville, Alabama, that was under development on the acquisition date, was opened in the fourth quarter of 2014.
	On October 31, 2014, our wholly-owned subsidiary, ACSH Georgia purchased from Thinh D. Nguyen, M.D. and Han C. Phan all of the outstanding membership units of MedHelp, LLC, which operates an urgent-care center in Alpharetta, Georgia.
	On December 31, 2014, our wholly-owned subsidiary, ACSH Urgent Care of Virginia, LLC or ACSH Virginia, purchased from Stat Medical Care, P.C. and other sellers substantially all of the assets and assumed certain liabilities used in the operation of two urgent care centers located in Fairfax and Gainesville, Virginia.
	In each of these transactions, a portion of the purchase price was paid in cash on the closing date, and the remainder of the purchase prices was paid by issuing promissory notes to the sellers. See Note 6 – Lines of Credit, Promissory Notes, and Notes Payable. After closing certain transactions, various working capital and other adjustments were made to the purchase price in the manner and amount set forth in the purchase agreements.  We also recorded valuation adjustments to the promissory notes to reflect differences between the notes' stated interest rates and market interest rates on the acquisition dates.
	The following table provides a detailed breakdown of the purchase price that was paid in each acquisition:
		CorrectMed				Bay Walk-In				Mid-South			MedHelp			Stat Medical			Total
						Clinic				Urgent Care						Care
	Cash consideration in purchase agreement*	$	2,180			$	1,500			$	1,350		$	780		$	1,328		$	7,138
	Adjustments on closing date		4				-				34			13			-			51
	Cash consideration, as adjusted		2,184				1,500				1,384			793			1,328			7,189
	Deferred consideration in purchase agreement		500				700				150			100			50			1,500
	Adjustments for working capital		(46	)			(170	)			15			(15	)		-			(216	)
	Valuation adjustments to promissory notes		11				(6	)			5			2			1			13
	Deferred consideration, as adjusted		465				524				170			87			51			1,297
	Total Purchase Price	$	2,649			$	2,024			$	1,554		$	880		$	1,379		$	8,486
	*$268,000 was due to seller, Stat Medical Care, as of December 31, 2014.
	The assets and liabilities of the acquired business were recorded in the Company's consolidated financial statements at their estimated fair values as of the acquisition date. The excess value of the consideration paid over the fair value of assets acquired and liabilities assumed is recorded as goodwill. Goodwill arising from the acquisition consists largely from a trained workforce in place and expected synergies that we expect to receive by combining the operations of multiple urgent and primary care businesses.
	A summary of the assets acquired and liabilities assumed is as follows:
	Acquisition Activity
		CorrectMed				Bay Walk-In				Mid-South			MedHelp			Stat Medical			Total
						Clinic				Urgent Care						Care
	Accounts receivable	$	221			$	153			$	147		$	28		$	81		$	630
	Other current assets		48				-				32			37			-			117
	Property and equipment		1,325				63				1,205			180			211			2,984
	Identifiable intangible assets		110				97				105			600			60			972
	Goodwill		1,871				1,788				1,437			44			1,042			6,182
	Total assets acquired		3,575				2,101				2,926			889			1,394			10,885
	Liabilities assumed		(926	)			(77	)			(1,227	)		(9	)		(15	)		(2,254	)
	Deferred tax liability		-				-				(145	)		-			-			(145	)
	Net assets acquired	$	2,649			$	2,024			$	1,554		$	880		$	1,379		$	8,486
	The goodwill and other identifiable intangible assets generated from the CorrectMed, Bay Walk-In, MedHelp, and Stat Medical Care transactions are deductible for federal income tax purposes. The goodwill and other identifiable intangible assets generated from the Mid-South Urgent Care transaction are not deductible for federal income tax purposes.  We recorded a deferred tax liability of approximately $145,000 related to the non-deductibility and the basis differences on acquired assets.  As a result, our deferred tax asset valuation allowance was reduced by $145,000, which is reflected as a reduction in the income tax expense on the Consolidated Statements of Operations for the year ended December 31, 2014.
	The accounts receivable balance for Stat Medical Care is a preliminary amount and any adjustment in 2015 will result in a revision to goodwill.
	Approximately $333,000 of transaction costs were expensed related to these acquisitions during the year ended December 31, 2014.
	The following table provides certain pro forma financial information for the Company, as if the acquisition of CorrectMed had occurred on January 1, 2013.  Pro forma information for Bay Walk-In, Mid-South Urgent Care, MedHelp, and Stat Medical Care was not included since it was impracticable to obtain, due to the financial reporting approach utilized by the prior owners of the businesses.
		Year Ended December 31,
		2014				2013
	Net revenue
	Ancillary	$	23,146			$	26,751
	Urgent and primary care		3,268				3,654
	Total net revenue		26,414				30,405
	Net loss	$	(7,020	)		$	(4,921	)
	Loss per basic and diluted common share	$	(1.10	)		$	(0.86	)
	Using net revenue on a cash basis for all acquisitions, our total pro forma urgent and primary care net revenue was $7,678,000 and $6,949,000 for the years ended December 31, 2014 and 2013, respectively.
	The following table provides net revenues since acquisition for the period ending December 31, 2014.
		2014
	CorrectMed	$	2,144
	Bay Walk-In Clinic		719
	Mid-South Urgent Care		875
	MedHelp		168
	Stat Medical Care		-
Total	$	3,906

Note_4_Accounts_Receivable_and

Note 4 - Accounts Receivable and Revenue	12 Months Ended
	Dec. 31, 2014
Accounts Receivable And Revenue [Abstract]
Accounts Receivable And Revenue [Text Block]	4.  Accounts Receivable and Revenue
	Below is a summary of accounts receivable as of December 31, 2014, and revenues for the period ending December 31, 2014, for our urgent and primary care business.  We entered the urgent and primary care business in May 2014.
		2014
	Accounts receivable	$	2,434
	Less:
	Estimated allowance for uncollectible amounts		(847	)
	Accounts receivable, net	$	1,587
			2014
	Gross revenue	$	7,259
	Less:
	Provision for contractual adjustments and estimated uncollectible amounts		(3,353	)
	Net revenue	$	3,906
	For our ancillary network business, several clients comprised a significant portion of our net revenue during the years ended December 31, 2014 and 2013.  The following is a summary of the approximate amounts of our net revenue and accounts receivable attributable to our significant clients as of the dates and for the periods presented:
		2014								2013
		Accounts Receivable			Net Revenue		% of Total Revenue			Accounts Receivable		Net Revenue		% of Total Revenue
	HealthSmart Preferred Care II, L.P.	$	870		$	7,764		34	%	$	532	$	5,905		22	%
	HealthMarkets, Inc.		244			1,967		9	%		252		3,599		13	%
	Benefit Administrative Systems, LLC		179			1,818		8	%		148		2,618		10	%
	We maintain an allowance for uncollectible receivables which primarily relates to payor refunds.  Refunds are paid to payors for overpayments on claims, claims paid in error, and claims paid for non-covered services.  In some instances, we will recoup payment made to the ancillary service provider if the claim has been fully resolved. Co-payments, deductibles and co-insurance payments can also impact the collectability of claims. While we are able to process a claim and estimate the cash it will receive from the payor for that claim, the presence of co-pays, deductibles and co-insurance payments can affect the ultimate collectability of the claim. We record an allowance against revenue to better estimate collectability. Provisions for refunds recorded were approximately $60,000 and $287,000 for the years ended December 31, 2014 and 2013, respectively. The allowance was approximately $300,000 and $336,000 at December 31, 2014 and 2013, respectively.
	On October 1, 2014, we entered into a management services agreement with HealthSmart.  Under the management services agreement, HealthSmart has assumed responsibility for the operation of our ancillary network business. See Note 1 for significant terms of the management services agreement.
	Although the effective date of the management services agreement with HealthSmart was October 1, 2014, the transition to HealthSmart did not begin until November 1, 2014. Upon reconciliation of all fourth quarter activity, we determined that we owed HealthSmart approximately $903,000, which was comprised of $560,000 in expense reimbursements and $343,000 for its share of the net profit as calculated per the management services agreement.

Note_5_Capital_and_Operating_L

Note 5 - Capital and Operating Lease Obligations	12 Months Ended
	Dec. 31, 2014
Leases [Abstract]
Leases of Lessee Disclosure [Text Block]	5.  Capital and Operating Lease Obligations
	In conjunction with our urgent and primary care acquisitions during the year ended December 31, 2014, we assumed and entered into various capital and operating leases expiring at various dates through January 2040.  The following is a schedule of the future required payments under these lease agreements for the years ending December 31:
					Operating		Total
		Capital Leases			Leases
	2015	$	280		$	729	$	1,009
	2016		299			879		1,178
	2017		287			766		1,053
	2018		276			651		927
	2019		273			585		858
	Thereafter		2,898			827		3,725
	Total minimum lease payments		4,313		$	4,437	$	8,750
	Less amount representing interest		(2,432	)
	Present value of net minimum obligations		1,881
	Less current obligation under capital lease		117
	Long-term obligation under capital lease	$	1,764

Note_6_Lines_of_Credit_Promiss

Note 6 - Lines of Credit, Promissory Notes, and Notes Payable	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	6.  Lines of Credit, Promissory Notes, and Notes Payable
	Below is a summary of our short-term and long-term debt obligations.
	Lines of Credit
	On July 30, 2014, we entered into a credit agreement with Wells Fargo Bank, National Association, or Wells Fargo, providing for a $5,000,000 revolving line of credit.  On December 4, 2014, we entered into a second credit agreement with Wells Fargo Bank, providing for a $6,000,000 revolving line of credit.  We refer to these two agreements as our credit agreements.  Our obligation to repay advances under the credit agreements are evidenced by the revolving line of credit notes, with a fluctuating interest rate per annum of 1.75% above daily one month LIBOR, as in effect from time to time.  The credit agreements mature on June 1, 2016, and all borrowings under the credit agreements are due and payable on that date.  The obligations under the credit agreements are secured by all the assets of the Company and its subsidiaries.  The credit agreements include ordinary and customary covenants related to, among other things, additional debt, further encumbrances, sales of assets, and investments and lending.
	Borrowings under the credit agreements are also secured by guarantees provided by certain officers and directors of the Company, among others.  On July 30, 2014, we issued to the guarantors of the July 2014 obligations warrants to purchase an aggregate of 800,000 shares of our common stock at $3.15 per share in consideration of their guaranteeing such indebtedness. The July 2014 warrants vested immediately and are exercisable any time prior to their expiration on October 30, 2019.  In addition, on December 4, 2014, we issued to the guarantors of the December 2014 obligations warrants to purchase an aggregate of 960,000 shares of our common stock at $2.71 per share in consideration of their guaranteeing such indebtedness. The December 2014 warrants vested immediately and are exercisable any time prior to their expiration on December 4, 2019.  See Note 13 - Warrants.
	As of December 31, 2014, we had outstanding borrowings of $4,716,000 under our July 2014 credit agreement, which were recorded as a long-term liability on our consolidated balance sheet as of December 31, 2014. Substantially all of the borrowings were used to finance acquisition activity.  The weighted-average interest rate on these borrowings was 1.92%.  As of December 31, 2014, we had no borrowings outstanding under the December 2014 credit agreement.
	Promissory Notes and Notes Payable
	In connection with our acquisition activities during the year ended December 31, 2014, our subsidiaries executed and delivered promissory notes to partially finance the transactions. The following is a summary of the promissory notes issued in connection with the acquisition activities during the year ended December 31, 2014:
		Issue Date		Fair Value Principal			Interest Rate per		Maturity Date
				Amount¹			Annum
	CorrectMed	8-May-14		$	465		5	%	8-May-15
	Bay Walk-In	29-Aug-14			30		5	%	29-Aug-16
	Bay Walk-In	29-Aug-14			205		5	%	29-Aug-16
	Bay Walk-In	29-Aug-14			289		none		28-Feb-17
	Mid-South	12-Sep-14			170	*	5	%	12-Sep-16
	MedHelp	31-Oct-14			87	*	5	%	31-Oct-15
	Stat Medical Care	31-Dec-14			51	*	5	%	31-Dec-15
	Total			$	1,297
	¹Amounts include working capital and valuation adjustments
	*Promissory notes issued to seller physicians are related parties. See Note 16 – Related Party Transactions.
	After making the valuation adjustments, interest is being accrued for accounting purposes at rates ranging from 2.5% to 3%.  As payments are made, the principal portion and interest expense are recognized using the effective interest method.
	The following is a summary of all debt as of December 31, 2014:
	Revolving line of credit		$	4,716
	Promissory notes, related to acquisitions			1,263
	Note payable			38
	Total debt			6,017
	Less current maturities			989
	Long-term debt		$	5,028
	Outstanding debt balances as of December 31, 2014 mature as follows: 2015 - $989,000; 2016 - $4,986,000; 2017 - $28,000; 2018 - $8,000; and 2019 - $6,000.

Note_7_Accrued_Liabilities

Note 7 - Accrued Liabilities	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	7.  Accrued Liabilities
	The following table summarizes accrued liabilities for years ended December 31:
		Year Ended December 31,
		2014		2013
	Purchase price due to seller, Stat Medical	$	268		$	-
	Accrued management fees		218			173
	Personnel-related		344			122
	Professional fees		146			180
	Accrued other		899			323
	Total	$	1,875		$	798

Note_8_Property_and_Equipment

Note 8 - Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	8.  Property and Equipment
	Property and equipment, net consists of the following:
		Useful Lives			2014			2013
		(years)
	Software - internally-developed		5		$	3,054		$	2,877
	Software - purchased	3	-	5		152			596
	Computer equipment	3	-	5		613			589
	Medical equipment		5			626			-
	Furniture and fixtures		5			390			358
	Vehicles		5			43			-
	Leasehold improvements		7			2,151			205
						7,029			4,625
	Accumulated depreciation and amortization					(2,707	)		(3,389	)
	Property and equipment, net				$	4,322		$	1,236
	We recognized depreciation expense of approximately $691,000 and $667,000 during 2014 and 2013, respectively.  The depreciation amounts include approximately $432,000 and $503,000 of amortization of internally-developed software during 2014 and 2013, respectively.
	We capitalize costs associated with internally-developed software, developed for internal use only, during the application development stage.  Application development stage costs generally include costs associated with internal-use software configuration, coding, installation, and testing. Costs of significant upgrades and enhancements that result in additional functionality also are capitalized, whereas costs incurred for maintenance and minor upgrades and enhancements are expensed as incurred. Capitalized costs include external direct costs of materials and services utilized in developing or obtaining internal-use software and payroll and payroll-related expenses for employees who are directly associated with and devote time to the internal-use software project.  Capitalization of such costs begins when the preliminary project stage is complete and ceases no later than the point at which the project is substantially complete and ready for its intended purpose.
	During the years ended December 31, 2014 and 2013, we capitalized costs related to enhancements to its internal information technology claims management applications.  The applications were originally developed in 2005, and from time to time, we will enhance the functionality and reporting capabilities of the applications.  The enhancements are typically developed by our internal information technology group.  For internal resources, we capitalize salary and related benefits. Periodically, third-party consultants will be utilized to perform the development with all related costs capitalized.

Note_9_Goodwill_and_Intangible

Note 9 - Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	9.  Goodwill and Intangible Assets
	Intangibles acquired in the urgent and primary care transactions during 2014 are comprised of relationships with patients and related contracts that drive volume into the acquired centers and results in a repeatable revenue stream.  The remaining excess purchase price of $6,182,000 was allocated to goodwill and is not subject to amortization.
	Intangible assets and related accumulated amortization consists of the following as of the dates presented:
		31-Dec-14			31-Dec-13
	Gross carrying amount of urgent and primary care intangibles:
	Patient relationships and contracts	$	972		$	-
	Accumulated amortization		(47	)		-
	Urgent and primary care intangibles, net		925			-
	Gross carrying amount of ancillary intangibles:
	Ancillary provider network		1,921			1,921
	Software		428			428
			2,349			2,349
	Accumulated amortization		(1,837	)		(1,709	)
	Other intangibles, net		512			640
	Total intangibles, net	$	1,437		$	640
	Total amortization expense related to intangibles was approximately $175,000 and $128,000 during the years ended December 31, 2014 and 2013, respectively.   The patient relationships and contracts are being amortized using the straight-line method over their estimate useful lives of five (5) years.  The ancillary provider network is being amortized using the straight-line method over its expected useful lives of 15 years.  Experience-to-date is that approximately 2%-8% annual turnover or attrition of provider contracts occurs each year.  The ancillary provider network is being accounted for on a pooled basis and the actual cancellation rates of provider contracts that were acquired are monitored for potential impairment or amortization adjustment, if warranted.
	Estimated annual amortization expense relating to intangibles is as follows:
	Years ending December 31,	Urgent and			Ancillary Care			Total
		Primary Care			Services
	2015	$	194		$	128		$	322
	2016		194			128			322
	2017		194			128			322
	2018		194			128			322
	2019		149			-			149
	Total	$	925		$	512		$	1,437

Note_10_Private_PlacementEquit

Note 10 - Private Placement/Equity	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	10.  Private Placement/Equity
	On May 5, 2014, we closed a private placement of 1,000,000 shares of our common stock at a purchase price of $2.00 per share for an aggregate purchase price of $2,000,000 for the shares. The investors in the offering included, among others, John Pappajohn, Mark C. Oman and Matt Kinley, who are each directors of the Company.

Note_11_Income_Taxes

Note 11 - Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	11.  Income Taxes
	Income tax provision for the years ended December 31, 2014 and 2013, differed from the U.S. federal income tax rate of approximately 34% in the amounts indicated as a result of the following:
		2014			2013
	Computed "expected" tax provision (benefit)	$	(2,276	)	$	(1,278	)
	Increase in the valuation allowance for deferred tax assets		2,287			1,009
	Shortfall on stock options, warrants, and RSUs		215			330
	State taxes		12			19
	Permanent items		45			12
	Tax benefit recognized related to stock acquisition		(145	)		-
	Other		(68	)		(67	)
	Total income tax provision	$	70		$	25
	Differences between financial accounting principles and tax laws cause differences between the basis of certain assets and liabilities for financial reporting purposes and tax purposes.  The tax effects of these differences, to the extent they are temporary, are recorded as deferred tax assets and liabilities and consist of the following:
		2014			2013
	Deferred tax assets:
	Operating loss carryforward	$	4,951		$	3,197
	Accounts receivable allowance		401			69
	Texas tax credit carryforward		215			221
	Stock option compensation		1,121			1,070
	Goodwill and intangibles		403			602
	Finance costs		209			-
	Accrued expenses		209			120
	Alternative Minimum Tax credit carryforwards		16			16
	Total deferred tax assets		7,525			5,295
	Deferred tax liabilities:
	Property and equipment		(518	)		(397	)
	Prepaid expense		(96	)		(71	)
	Total deferred tax liabilities		(614	)		(468	)
	Valuation allowance		(6,893	)		(4,606	)
	Net deferred tax assets	$	18		$	221
	During the years ended December 31, 2014 and 2013, we increased the valuation allowance by approximately $2,287,000 and $1,009,000, respectively, which was included in the income tax provision for the years ended December 31, 2014 and 2013.  Due to the nature and timing of the reversal of the deferred tax assets and liabilities, the valuation allowance was established against the net deferred tax assets with the exception of a portion of the Texas tax credit carryforward of approximately $18,000.
	As of December 31, 2014 and 2013, the net operating loss carryforwards were approximately $19,600,000 and $14,500,000, respectively, which expire from 2025 through 2034.  Included in the net operating loss carryforward is approximately $5,400,000 which related to the excess tax benefits for stock options and warrants exercised which will result in a credit to additional paid-in capital of approximately $1,900,000 when the associated tax deduction results in a reduction in the income taxes payable.
	The income tax provision shown on the statements of operations for the years ended December 31, 2014 and 2013 consisted of the following:
		2014			2013
	Current	$	12		$	18
	Deferred		58			7
		$	70		$	25

Note_12_Stockbased_Compensatio

Note 12 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	12.  Stock-Based Compensation
	Stock Options
	The Company maintains a Stock Option Plan (the "2005 Plan") for the benefit of certain employees, non-employee directors, and key advisors.  The 2005 Plan was approved by the stockholders on May 16, 2005.  The 2005 Plan (i) authorized options to purchase 749,776 shares and (ii) established the class of eligible participants to include employees, nominees to the Board of Directors of the Company and consultants engaged by the Company, limited to 16,667 shares of common stock underlying the one-time grant of a Non-Qualified Option to which non-employee directors or non-employee nominees of the Board of Directors may be entitled.  Stock options granted under the 2005 Plan may be of two types:  (1) incentive stock options and (2) nonqualified stock options.  The option price of such grants is determined by a Committee of the Board of Directors (the "Committee"), but in no case will such price be less than the estimated fair value of the common stock at the date the option is granted.  The Committee fixes the terms of the grants with no option term lasting longer than ten years.  The ability to exercise such options is determined by the Committee when the options are granted.
	Over time, the 2005 Plan has been amended to increase the number of shares available to a total of 1,249,776 shares.
	On May 19, 2009, stockholders of the Company approved the 2009 Equity Incentive Plan (the "2009 Plan").  The purpose of the 2009 Plan is (a) to allow selected employees and officers of the Company to acquire and increase equity ownership in the Company, which will strengthen their commitment to the success of the Company, and to attract new employees, officers and consultants; (b) to provide annual cash incentive compensation opportunities that are competitive with other peer corporations; (c) to optimize the profitability and growth of the Company through incentives that are consistent with the Company's goals; (d) to provide grantees an incentive for individual excellence; (e) to promote teamwork; and (f) to attract and retain highly-qualified persons to serve as non-employee directors.  The 2009 Plan allows for awards of non-qualified options, stock appreciation rights, restricted shares, performance units/shares, deferred stock, dividend equivalents and other stock-based awards up to 500,000 shares.  The term of the 2009 Plan is ten years and all non-qualified options will be valued at not less than 100% of the market value of the Company's stock on the date of grant. On June 3, 2014, stockholders voted to increase the number of shares subject to the 2009 Plan from 500,000 shares to 2,000,000 shares.
	Shares of common stock reserved for future grants under the Stock Option Plan and the 2009 Plan (the "Plans") were 1,381,914 and 482,083 at December 31, 2014 and 2013, respectively.
	Compensation expense related to all equity awards, including non-qualified stock options, incentive stock options, and restricted stock units, that has been charged against income for the years ended December 31, 2014 and 2013, was approximately $592,000 and $299,000, respectively.
	The awards granted to employees and non-employee directors become exercisable over periods of up to five years.  The fair value of each award granted is estimated on the date of grant using the Black-Scholes valuation model that uses the assumptions noted in the following table.  Volatility is calculated using an analysis of historical volatility.  The expected lives of options and forfeiture rates are determined based on our historical share option exercise experience.  We believe the historical experience method is the best estimate of future exercise patterns currently available.  The risk-free interest rates are determined using the implied yield currently available for zero-coupon U.S. government issues with a remaining term equal to the expected life of the awards.  The expected dividend yields are based on the approved annual dividend rate in effect and current market price of the underlying common stock at the time of grant.
	The following table presents the weighted-average assumptions used to estimate the fair value of options granted during the periods presented:
		2014			2013
	Weighted-average grant date fair value	$	2		$	1.01
	Weighted-average assumptions used:
	Expected volatility		72.8	%		77.7	%
	Expected lives (years)		5			6.2
	Risk free interest rate		1.7	%		1	%
	Forfeiture rate		29.5	%		20.5	%
	Dividend rate		0	%		0	%
	A summary of stock option activity is as follows:
		Options			Weighted-Average
					Exercise Price
	Outstanding at December 31, 2012		792		$	6.06
	Granted		284			1.88
	Forfeited		(113	)		2.88
	Cancelled		(208	)		6.99
	Exercised		(5	)		0.93
	Outstanding at December 31, 2013		750			4.74
	Granted		734			2.26
	Forfeited		(214	)		2.13
	Cancelled		(25	)		6.34
	Outstanding at December 31, 2014		1,245		$	3.69
	Exercisable at December 31, 2014		543		$	5.51
	As of December 31, 2014, the weighted-average remaining contractual life of the options outstanding was 6.6 years and the weighted-average remaining contractual life of the outstanding exercisable options was 3.2 years.
	The following table summarizes information concerning outstanding and exercisable options at December 31, 2014:
		Options Outstanding						Options Exercisable
	Range of Exercise Price	Number		Weighted-	Weighted-			Number	Weighted-
		Outstanding		Average	Average			Exercisable	Average
				Outstanding	Exercise				Exercise
				Contractual Life	Price				Price
	Under $1.00	53		0.5	$	0.93		52	$	0.93
	$1.00- $2.00	645		8.3		1.87		160		1.83
	$2.01- $3.00	87		9.54		2.81		-		-
	$3.01- $4.00	130		9.54		3.32		8		3.2
	$4.01- $5.00	25		3.49		4.24		24		4.24
	$5.01- $6.00	96		2.29		5.56		96		5.56
	$6.01- $7.00	84		2.49		6.14		78		6.14
	Greater than $7.01	125		2.16		12.08		125		12.08
		1,245		6.64	$	3.69		543	$	5.51
	The total intrinsic value of options outstanding at December 31, 2014 and 2013 was approximately $774,000 and $46,000, respectively.  The total intrinsic value of the options that are exercisable at December 31, 2014 and 2013 was approximately $274,000 and $40,000, respectively. There were 308 and 5,411 shares exercised during the years ended December 31, 2014 and 2013, respectively, with intrinsic values of approximately $390 and $5,000, respectively.
	Compensation expense related to stock options charged to operations during 2014 and 2013 was approximately $384,000 and $247,000, respectively.   As of December 31, 2014, there was approximately $894,000 of total unrecognized compensation cost related to non-vested non-qualified stock options granted under the plan.  The cost is expected to be recognized over a weighted-average period of 4.1 years.
	Restricted Stock Units
	In 2009, we issued restricted stock units ("RSUs") to certain employees and members of our Board of Directors.   As RSUs vest, they are convertible into shares of our common stock.  The RSUs are valued at the market price of our stock on the measurement date, which is the date of grant. Compensation expense is recognized ratably over the vesting period.  Our future estimated forfeiture rate on RSUs is 5% as the RSUs have been awarded primarily to members of our Board of Directors and members of our senior management.   At the Annual Meeting on May 30, 2013, the Board approved a compensation program that provides an annual grant of RSUs to directors on the date of our annual meeting of stockholders.  Pursuant to the program, 50,000 RSUs were awarded during each of the years ended December 31, 2014 and 2013.  An additional 55,000 RSUs were awarded to members of senior management of the Company during the twelve months ended December 31, 2014.
	A summary of RSU activity is as follows:
		RSUs			Weighted-Average
					Grant Date Fair Value
	Outstanding at December 31, 2012		4		$	21.4
	Granted		50			1.99
	Forfeited		(1	)		21.63
	Converted to common stock		(2	)		21.32
	Outstanding at December 31, 2013		51			2.4
	Granted		105			3.49
	Outstanding at December 31, 2014		156		$	3.08
	Vested and convertible to common stock at December 31, 2014		56		$	2.65
	Compensation expense related to RSUs charged to operations during 2014 and 2013 was approximately $208,000 and $52,000, respectively.  As of December 31, 2014, there was approximately $219,000 of total unrecognized compensation cost related to non-vested RSUs granted under the plan.  The cost is expected to be recognized over a weighted-average period of 1.5 years.
	At December 31, 2014, we had outstanding RSUs for 155,663 shares of our common stock. This includes 100,660 RSUs we awarded to our directors in 2009, 2013 and 2014 that were not, and would not, be in compliance with the terms of our 2009 Plan.  Because of such noncompliance, awards of RSUs to our directors and issuance of our common stock upon vesting of those RSUs have not been approved by our stockholders, and, accordingly, the issuance of our common stock thereunder was not and would not be in compliance with NASDAQ Listing Rule 5635(c). On November 5, 2014, we notified the NASDAQ Stock Market LLC, or NASDAQ, of these events and advised it that our Board of Directors has determined that we would suspend the issuance of additional common stock under the RSUs awarded in 2009 and would not issue any common stock under the RSUs awarded in 2013 or 2014 until stockholder approval of such awards is obtained and stockholders approve an amendment of the 2009 Plan to permit the award of RSUs to our directors. We also notified NASDAQ that we would seek such stockholder approval at our 2015 annual meeting of stockholders. On November 25, 2014, we received a letter from NASDAQ notifying us that NASDAQ had determined that we had violated NASDAQ Listing Rule 5635(c). In its November 25, 2014 letter, NASDAQ granted us an extension of time until May 26, 2015 to obtain such approvals and notify NASDAQ of such action.

Note_13_Warrants

Note 13 - Warrants	12 Months Ended
	Dec. 31, 2014
Warrants [Abstract]
Warrants [Text Block]	13.  Warrants
	The Company had 1,782,222 and 22,222 outstanding warrants to purchase common stock as of December 31, 2014 and December 31, 2013, respectively. 1,760,000 of those warrants at December 31, 2014 are considered derivative warrants because they contain exercise-price adjustment features. The remaining 22,222 non-derivative warrants as of December 31, 2014 and 2013 expire on February 25, 2016 and have an exercise price of $1.50 per share of common stock.
	July 30, 2014 Warrants
	On July 30, 2014, we issued warrants to individuals who provided guarantees in connection with a $5,000,000 line of credit that was obtained by us on that same date.  The warrants allow the warrant holders to purchase a total of 800,000 shares of our common stock for $3.15 per share, which was $0.01 per share higher than the closing market price of our common stock on July 30, 2014.  The warrants vested immediately and are exercisable any time prior to their expiration on October 30, 2019.  These warrants have anti-dilution provisions that could require some of the warrants' terms to change upon the occurrence of certain future events. Some of the anti-dilution provisions on warrants issued to our officers and directors do not become effective unless and until they are approved by our stockholders.  If approved, the anti-dilution provisions could result in changes to the warrants' strike price and the number of shares that can be purchased by the warrant holders. Because the strike price is not fixed, the warrants are reported as liabilities on our balance sheet.  On the date the warrants were issued, we recognized a warrant liability that was equal to the warrants' fair value of $1,420,000. A corresponding entry was made to deferred loan fees.
	Deferred loan fees are being amortized over the life of the line of credit agreement, which expires on June 1, 2016.  During the year ended December 31, 2014, we recognized $322,000 of amortization expense on this asset.
	The warrant liability is adjusted to the warrants' fair value at the end of each reporting period. Increases (decreases) in the warrant liability are reported as unrealized losses (gains) on the Company's statement of operations. On December 31, 2014, the warrants were adjusted to their estimated fair value of $1,410,000. The Company's statement of operations includes an unrealized gain of $10,000, which corresponds with the reduction in the liability since July 30, 2014.
	The warrants' fair value was calculated using the binomial options-pricing model.  In those calculations, we assumed that there was a 15% probability that the Company would have a private stock offering in the second half of 2015. If the market price of the Company's stock was less than the warrants' exercise price on the date of a private stock offering, we assumed that the warrants' exercise price would be reduced, and the number of shares purchasable by warrant holders would increase, in accordance with the terms of the warrant agreements. Additional assumptions we used in our valuation calculations were as follows:
		31-Dec-14			30-Jul-14
	Stock price	$	2.9		$	3.14
	Volatility		72.5	%		61.5	%
	Risk-free interest rate		1.65	%		1.83	%
	Exercise price	$	3.15		$	3.15
	Expected life (years)		4.83			5.25
	Dividend yield		0	%		0	%
	December 4, 2014 Warrants
	On December 4, 2014, we issued warrants to individuals who provided guarantees in connection with a $6,000,000 line of credit that was obtained by us on that same date.  The warrants allow the warrant holders to purchase a total of 960,000 shares of the common stock for $2.71 per share, which was equal to the closing market price of our common stock on December 4, 2014.  The warrants vested immediately and are exercisable any time prior to their expiration on December 4, 2019.  These warrants have anti-dilution provisions, under which the warrants' strike price could change if certain future events occur. Some of the anti-dilution provisions on warrants issued to the Company's officers and directors do not become effective unless and until they are approved by the Company's stockholders.  Because the strike price is not fixed, the warrants are reported as liabilities on our balance sheet.  On the date the warrants were issued, we recognized a warrant liability that was equal to the warrants' fair value of $1,660,000.  A corresponding entry was made to deferred loan fees.
	Deferred loan fees are being amortized over the life of the line of credit agreement, which expires on June 1, 2016.  During the year ended December 31, 2014, we recognized $92,000 of amortization expense on this asset.
	The warrant liability is adjusted to the warrants' fair value at the end of each reporting period.  Increases (decreases) in the warrant liability are reported as unrealized losses (gains) on our statement of operations.  On December 31, 2014, the warrants were adjusted to their estimated fair value of $1,790,000.  Our statement of operations includes an unrealized loss of $130,000, which corresponds with the increase in the liability since December 4, 2014.
	The warrants' fair value was calculated using the binomial options-pricing model.  In those calculations, we assumed that there was a 100% probability that the Company would have a public or private stock offering in the second half of 2015. If the market price of the Company's stock was less than the warrants' exercise price on the date of a stock offering, we assumed that the warrants' exercise price would be reduced, in accordance with the terms of the warrant agreements.  Additional assumptions we used in our valuation calculations were as follows:
		31-Dec-14			4-Dec-14
	Stock price	$	2.9		$	2.71
	Volatility		72.5	%		72.5	%
	Risk-free interest rate		1.65	%		1.59	%
	Exercise price	$	2.71		$	2.71
	Expected life (years)		4.93			5
	Dividend yield		0	%		0	%
	The Company did not have any derivative warrants outstanding on December 31, 2013. The following table summarizes the derivative warrant activity in 2014:
		Weighted-			Warrants			Warrants		Warrants
		Average			Outstanding			Issued		Outstanding
		Exercise			December 31,			in 2014		December 31,
		Price			2013					2014
	Warrants issued July 30, 2014	$	3.15			-			800		800
	Warrants issued December 4, 2014	$	2.71			-			960		960
	Total	$	2.91			-			1,760		1,760
	The following table summarizes the changes in the derivative warrants' fair values in 2014:
		Warrants			Warrants			Total
		Issued on			Issued on
		30-Jul-14			4-Dec-14
	Fair value of outstanding warrants as of December 31, 2013	$	-		$	-		$	-
	Fair value of warrants issued on July 30, 2014		1,420			-			1,420
	Fair value of warrants issued on December 4, 2014		-			1,660			1,660
	Fair value of warrants issued in 2014		1,420			1,660			3,080
	Change in fair value of warrants in 2014		(10	)		130			120
	Fair value of outstanding warrants as of December 31, 2014	$	1,410		$	1,790		$	3,200

Note_14_Fair_Value_of_Financia

Note 14 - Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	14.  Fair Value of Financial Instruments
	The Company adjusts its warrant derivative liability to fair value at the end of each reporting period. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. Assets and liabilities recorded at fair value are measured and classified in accordance with a three-tier fair value hierarchy based on the observability of the inputs available in the market used to measure fair value:
	Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets that we have the ability to access as of the measurement date.
	Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.
	Level 3: Significant unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing an asset or liability.
	The Company classifies its fair value measurements for the warrant derivative liability under Level 3, because the valuation models require certain unobservable inputs that may have a material impact on fair value. A table summarizing the activity for the derivative warrant liability is presented in Note 13.

Note_15_Employee_Benefit_Plans

Note 15 - Employee Benefit Plans	12 Months Ended
	Dec. 31, 2014
Significant Agreements [Abstract]
Significant Agreements [Text Block]	15.  Employee Benefit Plans
	We provide a defined contribution plan for all full-time, permanent employees. Eligible employees may contribute up to 100% of their current compensation to the plan subject to certain statutory limitations.  We contribute up to a maximum of 3.5% of an employee's compensation and plan participants are fully vested in our contributions immediately.  We made contributions to the plan and charged operations of approximately $109,000 and $98,000 during the years ended December 31, 2014 and 2013, respectively.

Note_16_Related_Party_Transact

Note 16 - Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	16.  Related Party Transactions
	On January 10, 2014, we entered into an arrangement with Equity Dynamics, Inc. for monthly strategic consulting services.  Such services include acquisition activities and the securing of debt financing.  As part of the arrangement, Equity Dynamics, Inc. will receive a monthly fee of $10,000 for performance of such consulting services.  Equity Dynamics, Inc. is a company owned by John Pappajohn, and Matt Kinley serves as its Executive Vice President.  Mr. Pappajohn and Mr. Kinley are both members of our Board of Directors.
	In addition, see discussion of other related party transactions in Note 10 - Private Placement/Equity and Note 13 - Warrants.
	In connection with the acquisitions of Mid-South, MedHelp, and Stat Medical Care, we retained the seller physicians as employees upon closing. Refer to Note 6 - Lines of Credit, Promissory Notes, and Notes Payable for the terms of the promissory notes.

Note_17_Segment_Reporting

Note 17 - Segment Reporting	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	17.  Segment Reporting
	We evaluate performance based on several factors, of which the primary financial measure for each segment is operating income.  We define segment operating income for our business segments as income before interest expense, gain or loss on disposal of assets, income taxes, depreciation expense, non-cash amortization of intangible assets, non-cash stock-based compensation expense, shared services, severance charges and any non-recurring costs such as transactional costs related to our acquisition program.  Shared services primarily consist of compensation costs for the executive management team, facilities' costs for our corporate headquarters, shared services such as finance and accounting, human resources, legal, marketing and information technology and general administration.  Shared services also includes transactional costs.
	The following tables set forth a comparison of operations for the following periods presented for our two lines of business and shared services (certain prior year amounts have been reclassified for comparability purposes).
	Consolidated statements of operations by segment for the respective years ended December 31, are as follows:
		2014												2013
		Urgent and			Ancillary			Shared			Total			Urgent and		Ancillary		Shared			Total
		Primary Care			Network			Services						Primary Care		Network		Services
	Net revenues	$	3,906		$	23,146		$	-		$	27,052		$	-	$	26,751	$	-		$	26,751
	Total segment operating income (loss)		(80	)		1,353			(5,360	)		(4,087	)		-		1,096		(3,535	)		(2,439	)
	Additional Segment Disclosures:
	Interest expense, including loan fee amortization		658			-			-			658			-		-		-			-
	Depreciation and amortization expense		222			644			-			866			-		795		-			795
	Income tax expense (benefit)		(145	)		215			-			70			-		25		-			25
	Total asset expenditures		347			429			40			816			-		315		-			315
	The following provides a reconciliation of reportable segment operating income (loss) to the Company’s consolidated totals:
		2014			2013
	Total segment operating loss	$	(4,087	)	$	(2,439	)
	Less (add):
	Severance charges		108			199
	Non-recurring transaction costs		333			50
	Depreciation and amortization expense		866			795
	Non-cash stock-based compensation expense		592			299
	Other		166			-
	Operating loss		(6,152	)		(3,782	)
	Interest expense		658			-
	(Gain)/loss on disposal of assets		(108	)		5
	Interest income		(9	)		(27	)
	Loss before income taxes	$	(6,693	)	$	(3,760	)
	Segment assets include accounts receivable, prepaid expenses and other current assets, property and equipment, and intangibles.  Shared services assets consist of cash and cash equivalents, prepaid insurance, deferred income taxes and property and equipment primarily related to information technology assets.  Consolidated assets, by segment and shared services, as of the periods presented are as follows:
		Urgent and			Ancillary Network			Shared Services			Consolidated
		Primary Care
	31-Dec-14	$	11,958		$	5,202		$	3,945		$	21,105
	31-Dec-13		-			4,404			6,625			11,029

Note_18_Litigation_Contingenci

Note 18 - Litigation Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	18.  Litigation Contingencies
	As of December 31, 2014, we were not involved in, but may in the future be involved in, legal proceedings, claims and governmental investigations in the normal course of business. Legal fees and other costs associated with such actions are expensed as incurred. We assess, in conjunction with our legal counsel, the need to record a liability for litigation and contingencies. Litigation accruals are recorded when and if it is determined that a loss related matter is both probable and reasonably estimable. Material loss contingencies that are reasonably possible of occurrence, if any, are subject to disclosure. As of December 31, 2013 and December 31, 2014, there was no litigation or contingency with at least a reasonable possibility of a material loss.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation
	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries.  All material intercompany accounts and transactions are eliminated in consolidation.
	Certain amounts in the December 2013 income statement presentation were reclassified to conform to the December 2014 presentation. There is no impact on major classifications or net loss due to these reclassifications.
Liquidity Disclosure [Policy Text Block]	Liquidity
	During 2014, we made significant investments in our urgent and primary care business.  We used working capital, proceeds from a private equity offering, bank debt and seller financed debt to consummate five transactions totaling $8,486,000, resulting in our acquisition of ten urgent and primary care centers.   We expanded our shared services function to provide the needed infrastructure to manage our urgent and primary care centers and support the planned growth of this business segment.  As a result of these efforts, losses related to the shared services function, as reported in Note 17, increased by $1,825,000 to $5,360,000, during the year ended December 31, 2014, compared to $3,535,000 during the year ended December 31, 2013.
	Our loss from operations increased by $2,370,000 to $6,152,000 during the year ended December 31, 2014 compared to $3,782,000 during the year ended December 31, 2013.  The increase in our operating loss resulted from expanding our shared services function, costs to build out and enhance our current urgent and primary care centers and the continuing decline in our ancillary network business.  As a result of our operating losses, we used cash in our operations of $4,034,000 and $4,188,000 during the years ended December 31, 2014 and 2013, respectively.  We anticipate we will continue to generate operating losses, and use cash in our operations, during the next 12 months, but have made changes to our business model to improve our operating results.  We believe the management service agreement we entered into with HealthSmart, to manage our ancillary network business, will reduce our operating costs.  We will continue to analyze other strategies to improve our ancillary network operating results. Also, we expect to realize the benefits of economies of scale as we acquire additional urgent and primary care centers.
	Until we generate cash flows from operations, we are dependent on our existing lines of credit and outside capital to fund our operations and additional acquisitions.  Our plans to fund these needs include:
		·	Equity financing through the currently filed Form S-1 Registration Statement to sell additional shares of our common stock.  If the offering is fully subscribed, we will raise an additional $15,000,000 (less applicable fees), plus any proceeds we would receive on account of the over allotment options we granted to underwriters.  We anticipate closing this offering during the second quarter of 2015.
		·	Use of our existing lines of credit, which as of March 30, 2015, collectively have $4,000,000 of borrowing capacity.
		·	If necessary, raising additional financing through additional bank borrowing, additional private or public offerings or support from existing guarantors.
Segment Reporting, Policy [Policy Text Block]	Segment and Related Information – We use the "management approach" for reporting information about segments. The management approach is based on the way the chief operating decision-maker organizes segments within a company for making operating decisions and assessing performance. We analyzed our products and services, geography, legal structure, management structure and any other factors, and we determined that the business is comprised of two reporting segments: urgent and primary business and ancillary network business.  The five businesses acquired were determined to be individual operating segments which have been aggregated into the urgent and primary business.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates – The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  We consider our most significant estimates to be the collectability of revenue, payments due to providers (and resulting margin as a percentage of revenue), and valuations related to acquisitions and warrants.  Actual amounts could differ from those estimates.
Risks and Uncertainties [Policy Text Block]	Risks and Uncertainties – We operate in industries that are subject to intense competition, government regulation and rapid technological change.  Our operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risks, including risk of business failure.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents – We consider all highly-liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents include amounts in deposit accounts in excess of federally-insured limits.  We have not experienced any losses in such accounts.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition in Urgent and Primary Care Business – We have agreements with governmental and other third-party payors that provide for payments to us based on contractual adjustments to our established rates. Net revenue is reported at the time service is rendered at the estimated net realizable amounts, after giving effect to estimated contractual amounts from patients, third-party payors and others, and an estimate for bad debts.
	Contractual adjustments are accrued on an estimated basis in the period the related services are rendered, and adjusted in future periods as final settlements are determined.  We grant credit without collateral to our patients, who consist primarily of local residents insured by third-party payors.   A summary of the basis of reimbursement with major third-party payors is as follows:
	Commercial and HMO – We have entered into agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations. Billing methodologies under these agreements include discounts from established charges and prospectively determined rates.
	Medicare – Services rendered to Medicare program beneficiaries are recorded at prospectively determined rates. These rates vary according to a patient classification system that is based on clinical, diagnostic, and other factors.
	In establishing allowance for bad debts, we consider historical collection experience, the aging of the account, payor classification and patient payment patterns.  We adjust this allowance prospectively.
	Collection of payment for services provided to patients without insurance coverage is done at time of service.
	Revenue Recognition in Ancillary Network Business – We recognize revenue on the services that we provide, which includes (i) providing payor clients with a comprehensive network of ancillary healthcare providers; (ii) providing claims management, reporting, processing and payment services; (iii) providing network/need analysis to assess the benefits to payor clients of adding additional/different service providers to the client-specific provider networks; and (iv) providing credentialing of network service providers for inclusion in the client payor-specific provider networks.  Revenue is recognized when services are delivered, which occurs after processed claims are billed to the payor clients and collections are reasonably assured.  We estimate revenues and costs of revenues using average historical collection rates and average historical margins earned on claims.  Periodically, revenues are adjusted to reflect actual cash collections so that revenues recognized accurately reflect cash collected.
	We record a provision for refunds based on an estimate of historical refund amounts.  Refunds are paid to payors for overpayment on claims, claims paid in error, and claims paid for non-covered services.  In some instances, we will recoup payments made to the ancillary service provider if the claim has been fully resolved.  The evaluation is performed periodically and is based on historical data.  We present revenue net of the provision for refunds on the consolidated statement of operations.
	After careful evaluation of the key gross and net revenue recognition indicators, we have concluded that our circumstances are most consistent with those key indicators that support gross revenue reporting, since we are fulfilling the services of a principal versus an agent.
	Following are the key indicators that support our conclusion that we act as a principal when settling claims for service providers through our contracted service provider network:
		·	The Company is the primary obligor in the arrangement. We have assessed our role as primary obligor as a strong indicator of gross reporting.  We believe that we are the primary obligor in our transactions because we are responsible for providing the services desired by our payor clients.  We have distinct, separately negotiated contractual relationships with our payor clients and with the ancillary healthcare providers in our networks.  We do not negotiate "on behalf of" our payor clients and do not hold ourselves out as the agent of the payor clients when negotiating the terms of our ancillary healthcare service provider agreements.  Our agreements contractually prohibit payor clients and service providers from entering into direct contractual relationships with one another.  The payor clients have no control over the terms of our agreements with the service providers.  In executing transactions, we assume key performance-related risks.  The payor clients hold us responsible for fulfillment, as the provider, of all of the services the payor clients are entitled to under their contracts; payor clients do not look to the service providers for fulfillment.  In addition, we bear the pricing/margin risk as the principal in the transactions.  Because the contracts with the payor clients and service providers are separately negotiated, we have complete discretion in negotiating both the prices we charge our payor clients and the financial terms of our agreements with the service providers.  Because our profit is the spread between the amounts received from the payor clients and the amount paid to the service providers, we bear significant pricing and margin risk.  There is no guaranteed mark-up payable to us on the amount we have contracted.  Thus, we bear the risk that amounts paid to the service provider will be greater than the amounts received from the payor clients, resulting in a loss or negative claim.
		·	The Company has latitude in establishing pricing.  As stated above, we are able to negotiate the price payable to us by our payor clients as well as the price to be paid to each contracted service provider.  This type of pricing latitude indicates that we have the risks and rewards normally attributed to a principal in the transactions.
		·	The Company changes the product or performs part of the services. We provide the benefits associated with the relationships we build with the payor clients and the services providers.  While the parties could deal with each other directly, the payor clients would not have the benefit of our experience and expertise in assembling a comprehensive network of service providers, in claims management, reporting and processing and payment services, in performing network/needs analysis to assess the benefits to payor clients of adding additional/different service providers to the client payor-specific provider networks, and in credentialing network service providers.
		·	The Company has complete discretion in supplier selection. We have complete discretion in supplier selection.  One of the key factors considered by payor clients which engage us is to have the Company undertake the responsibility for identifying, qualifying, contracting with and managing the relationships with the ancillary healthcare service providers.  As part of the contractual arrangement between us and our payor clients, the payors identify their obligations to their respective covered persons and then work with us to determine the types of ancillary healthcare services required in order for the payors to meet their obligations.  We may select the providers and contract with them to provide services at its discretion.
		·	The Company is involved in the determination of product or service specifications. We work with our payor clients to determine the types of ancillary healthcare services required in order for the payors to meet their obligations to their respective covered persons.  In some respects, we are customizing the product through our efforts and ability to assemble a comprehensive network of providers for our payors that is tailored to each payor's specific needs.  In addition, as part of our claims processing and payment services, we work with the payor clients, on the one hand, and the providers, on the other, to set claims review, management and payment specifications.
		·	The supplier (and not the Company) has credit risk. We believe we have some level of credit risk, but that risk is mitigated because we do not remit payment to providers unless and until we have received payment from the relevant payor clients following our processing of a claim.
		·	The amount that the Company earns is not fixed. We do not earn a fixed amount per transaction nor do we realize a per-person per-month charge for our services.
	We have evaluated the other indicators of gross and net revenue recognition, including whether or not we have general inventory risk.  We do not have any general inventory risk, as our business is not related to the manufacture, purchase or delivery of goods and we do not purchase in advance any of the services to be provided by the ancillary healthcare service providers.  While the absence of this risk would be one indicator in support of net revenue reporting, as described in detail above, we have carefully evaluated all of the key gross and net revenue recognition indicators and have concluded that our circumstances are more consistent with those key indicators that support gross revenue reporting.
	If, however, we were to report our ancillary network revenues, net of provider payments rather than on a gross reporting basis, for the years ended December 31, 2014 and 2013, our revenues would have been approximately $6,900,000 and $7,000,000, respectively.
Cost of Sales, Policy [Policy Text Block]	Ancillary Network Provider Payments – Payments to providers is the largest component of our cost of revenues and it consists of payments for ancillary care services in accordance with contracts negotiated with providers for specific ancillary services, separately from contracts negotiated with our clients.
Advertising Costs, Policy [Policy Text Block]	Advertising Costs – Advertising costs are expensed as incurred.   Advertising expense for the years ended December 31, 2014 and 2013 was approximately $193,000 and $65,000, respectively.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment – Property and equipment are recorded at original cost and increased by the cost of any significant improvements subsequent to purchase.  Property and equipment acquired through acquisitions are recorded at their estimated fair market value on the date of acquisition. We expense repairs and maintenance as incurred.  Depreciation and amortization is calculated using the straight-line method over the shorter of the asset's estimated useful life or the term of the lease in the case of leasehold improvements. We capitalize costs associated with software developed for internal use. During 2014 and 2013, we capitalized approximately $177,000 and $303,000 of internally-developed software costs, respectively.
	Amortization of assets acquired under capital leases is included as a component of depreciation and amortization expense.  Amortization is calculated using the straight-line method over the shorter of the useful lives or terms of the underlying lease agreements.
Loan Guarantee Fees [Policy Text Block]	Deferred Loan Fees – Deferred loan fees related to the issuance of warrants in exchange for debt guarantees by certain directors/shareholders are amortized on a straight-line basis over the term of the debt.
Deferred Charges, Policy [Policy Text Block]	Deferred Offering Costs – Deferred offering costs represent legal, accounting and other direct costs related to raising capital through a stock offering.  Costs related to our planned offering activities are deferred until completion of the offering, at which time they are reclassified to additional paid-in capital as a reduction of the offering proceeds.  There were no offering costs in connection with our private placement in May 2014. In connection with our planned upcoming offering, approximately $225,000 of offering costs have been deferred.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets – Long-lived assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of an asset or group of assets might not be recoverable. We perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would indicate a potential impairment include a significant decline in the observable market value of an asset or a significant change in the extent or manner in which an asset is used. The impairment review includes a comparison of future projected cash flows generated by the asset or group of assets with its associated net carrying value. If the net carrying value of the asset or group of assets exceeds expected cash flows (undiscounted and without interest charges), an impairment loss is recognized to the extent the carrying amount of the asset or asset group exceeds its fair value.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill – Goodwill resulted from the acquisitions of urgent and primary care businesses during the year ended December 31, 2014.  See Note 3.  In accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 805, Business Combinations, the purchase method of accounting requires that the excess of the purchase price paid over the estimated fair value of identifiable tangible and intangible net assets of acquired businesses be recorded as goodwill.  In accordance with ASC 350, Intangibles – Goodwill and Other, we are required to test goodwill for impairment annually.  We established October 1 as the date of our annual impairment review.  We determined no impairment existed for the period ended September 30, 2014, and there were no factors identified that indicated impairment existed through December 31, 2014.
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Intangible Assets – Intangible assets are recorded at fair values at the date of acquisition. Our intangible assets have finite useful lives and are amortized over their estimated useful lives.
Derivatives, Policy [Policy Text Block]	Warrant Derivative Liability – We have issued certain warrants which contain an exercise price adjustment feature in the event we issue additional equity instruments at a price lower than the exercise price of the warrant.  The warrants are described herein as derivative warrants.  We account for these derivative warrants as liabilities. These common stock purchase warrants do not trade in an active securities market.  See Note 13 for methodology used to value warrants.
	We compute the fair value of the warrant liability at each reporting period and the change in the fair value is recorded in the statement of operations. The key component in the value of the warrant liability is our stock price, which is subject to significant fluctuation and is not under our control.   The resulting effect on our net income (loss) is, therefore, subject to significant fluctuation and will continue to be so until the warrants are exercised, amended or expire.  Assuming all other fair value inputs remain constant, we will record non-cash income/expense with changes in our stock price or when the underlying assumptions in calculating warrant value change.
Research and Development Expense, Policy [Policy Text Block]	Research and Development – Research and development costs are expensed as incurred.
Income Tax, Policy [Policy Text Block]	Income Taxes – Income taxes are accounted for under the asset and liability method.  Deferred taxes arise because of different treatment between financial statement accounting and tax accounting, known as "temporary differences".  We record the tax effect of these temporary differences as "deferred tax assets" (generally items that can be used as a tax deduction or credit in the future periods) and "deferred tax liabilities" (generally items that we received a tax deduction for, which have not yet been recorded in the statements of operations). The deferred tax assets and liabilities are measured using enacted tax rules and laws that are expected to be in effect when the temporary differences are expected to be recovered or settled. A valuation allowance is established to reduce deferred tax assets considered to be more-likely-than-not that the deferred tax assets will not be realized.
	ASC 740, Income Taxes, clarifies the accounting for uncertainty in income taxes recognized in the financial statements. ASC 740 provides that a tax benefit from uncertain tax positions may be recognized when it is more-likely-than-not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.  Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. ASC 740 also provides guidance on measurement, de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.  At December 31, 2014, and 2013, we had no uncertain tax positions.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation – We record all stock-based payments to employees in the consolidated financial statements over the vesting period based on our estimated fair values as of the measurement date of the respective awards.  Additional information about our stock-based payment plan is presented in Note 12.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value of Financial Instruments – The carrying amount of accounts receivable, accounts payable and accrued expenses, approximate their estimated fair values due to the short-term maturities of those financial instruments. These financial instruments are considered Level 3 measurements under the fair value hierarchy. The fair values of our promissory notes, notes payable, lines of credit and capital lease obligations approximate carrying value under Level 3 of the fair value hierarchy. The fair value of warrants recorded as derivative liabilities are described in Note 14.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements – In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 660): Summary and Amendments that Create Revenue from Contracts with Customers (Topic 606) and Other Assets and Deferred Costs-Contracts with Customers (Subtopic 340-40).  The guidance in this update supersedes the revenue recognition requirements in ASC Topic 605, Revenue Recognition, and most industry-specific guidance throughout the industry topics of the codification.  This guidance will be effective for interim and annual periods beginning after December 15, 2016.  We are currently assessing the impact that this guidance will have on our consolidated financial statements.
	In August 2014, the FASB ASU 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The guidance relates to the disclosures around going concern.  The new standard update provides guidance around management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures.  The new guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted. We do not believe the adoption of this guidance will have a material impact on our consolidated financial statements.
Earnings Per Share, Policy [Policy Text Block]	Earnings (Loss) Per Share – Basic earnings (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted-average number of common shares outstanding during the period of computation.  Diluted earnings per share is computed similar to basic earnings per share except that the numerator is adjusted for the change in fair value of the warrant liability (only if dilutive), and the denominator is increased to include the number of dilutive potential common shares outstanding during the period using the treasury stock method.
	The following table summarizes potentially dilutive shares outstanding as of December 31, 2014, which were excluded from the calculation due to being anti-dilutive:
			2014		2013
	Common stock purchase warrants			1,782		22
	Stock options			1,245		750
	Restricted shares of common stock			100		51

Note_2_Basis_of_Presentation_a1

Note 2 - Basis of Presentation and Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]		2014		2013
	Common stock purchase warrants		1,782		22
	Stock options		1,245		750
	Restricted shares of common stock		100		51

Note_3_Acquisitions_Tables

Note 3 - Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	Business Acquired	State		Sites			Date of		Purchase Price
							Closing
	CorrectMed	Georgia			2		8-May-14		$	2,649
	Bay Walk-In Clinic	Florida			2		29-Aug-14			2,024
	Mid-South Urgent Care	Alabama			3*		12-Sep-14			1,554
	MedHelp	Georgia			1		31-Oct-14			880
	Stat Medical Care	Virginia			2		31-Dec-14			1,379
	Total								$	8,486
Business Combination, Separately Recognized Transactions [Table Text Block]		CorrectMed				Bay Walk-In				Mid-South			MedHelp			Stat Medical			Total
						Clinic				Urgent Care						Care
	Cash consideration in purchase agreement*	$	2,180			$	1,500			$	1,350		$	780		$	1,328		$	7,138
	Adjustments on closing date		4				-				34			13			-			51
	Cash consideration, as adjusted		2,184				1,500				1,384			793			1,328			7,189
	Deferred consideration in purchase agreement		500				700				150			100			50			1,500
	Adjustments for working capital		(46	)			(170	)			15			(15	)		-			(216	)
	Valuation adjustments to promissory notes		11				(6	)			5			2			1			13
	Deferred consideration, as adjusted		465				524				170			87			51			1,297
	Total Purchase Price	$	2,649			$	2,024			$	1,554		$	880		$	1,379		$	8,486
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Acquisition Activity
		CorrectMed				Bay Walk-In				Mid-South			MedHelp			Stat Medical			Total
						Clinic				Urgent Care						Care
	Accounts receivable	$	221			$	153			$	147		$	28		$	81		$	630
	Other current assets		48				-				32			37			-			117
	Property and equipment		1,325				63				1,205			180			211			2,984
	Identifiable intangible assets		110				97				105			600			60			972
	Goodwill		1,871				1,788				1,437			44			1,042			6,182
	Total assets acquired		3,575				2,101				2,926			889			1,394			10,885
	Liabilities assumed		(926	)			(77	)			(1,227	)		(9	)		(15	)		(2,254	)
	Deferred tax liability		-				-				(145	)		-			-			(145	)
	Net assets acquired	$	2,649			$	2,024			$	1,554		$	880		$	1,379		$	8,486
Business Acquisition, Pro Forma Information [Table Text Block]		Year Ended December 31,
		2014				2013
	Net revenue
	Ancillary	$	23,146			$	26,751
	Urgent and primary care		3,268				3,654
	Total net revenue		26,414				30,405
	Net loss	$	(7,020	)		$	(4,921	)
	Loss per basic and diluted common share	$	(1.10	)		$	(0.86	)
Business Combination, Revenue Since Acquisition [Table Text Block]		2014
	CorrectMed	$	2,144
	Bay Walk-In Clinic		719
	Mid-South Urgent Care		875
	MedHelp		168
	Stat Medical Care		-
	Total	$	3,906

Note_4_Accounts_Receivable_and1

Note 4 - Accounts Receivable and Revenue (Tables)	12 Months Ended
	Dec. 31, 2014
Accounts Receivable And Revenue [Abstract]
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]		2014
	Accounts receivable	$	2,434
	Less:
	Estimated allowance for uncollectible amounts		(847	)
	Accounts receivable, net	$	1,587
Schedule of Revenue Sources, Health Care Organization [Table Text Block]			2014
	Gross revenue	$	7,259
	Less:
	Provision for contractual adjustments and estimated uncollectible amounts		(3,353	)
	Net revenue	$	3,906
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]		2014								2013
		Accounts Receivable			Net Revenue		% of Total Revenue			Accounts Receivable		Net Revenue		% of Total Revenue
	HealthSmart Preferred Care II, L.P.	$	870		$	7,764		34	%	$	532	$	5,905		22	%
	HealthMarkets, Inc.		244			1,967		9	%		252		3,599		13	%
	Benefit Administrative Systems, LLC		179			1,818		8	%		148		2,618		10	%

Note_5_Capital_and_Operating_L1

Note 5 - Capital and Operating Lease Obligations (Tables)	12 Months Ended
	Dec. 31, 2014
Leases [Abstract]
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]					Operating		Total
		Capital Leases			Leases
	2015	$	280		$	729	$	1,009
	2016		299			879		1,178
	2017		287			766		1,053
	2018		276			651		927
	2019		273			585		858
	Thereafter		2,898			827		3,725
	Total minimum lease payments		4,313		$	4,437	$	8,750
	Less amount representing interest		(2,432	)
	Present value of net minimum obligations		1,881
	Less current obligation under capital lease		117
	Long-term obligation under capital lease	$	1,764

Note_6_Lines_of_Credit_Promiss1

Note 6 - Lines of Credit, Promissory Notes, and Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Schedule of Promissory Notes Issued in Connection with Acquisition Activities [Table Text Block]		Issue Date		Fair Value Principal			Interest Rate per		Maturity Date
				Amount¹			Annum
	CorrectMed	8-May-14		$	465		5	%	8-May-15
	Bay Walk-In	29-Aug-14			30		5	%	29-Aug-16
	Bay Walk-In	29-Aug-14			205		5	%	29-Aug-16
	Bay Walk-In	29-Aug-14			289		none		28-Feb-17
	Mid-South	12-Sep-14			170	*	5	%	12-Sep-16
	MedHelp	31-Oct-14			87	*	5	%	31-Oct-15
	Stat Medical Care	31-Dec-14			51	*	5	%	31-Dec-15
	Total			$	1,297
Schedule of Debt [Table Text Block]	Revolving line of credit		$	4,716
	Promissory notes, related to acquisitions			1,263
	Note payable			38
	Total debt			6,017
	Less current maturities			989
	Long-term debt		$	5,028

Note_7_Accrued_Liabilities_Tab

Note 7 - Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]		Year Ended December 31,
		2014		2013
	Purchase price due to seller, Stat Medical	$	268		$	-
	Accrued management fees		218			173
	Personnel-related		344			122
	Professional fees		146			180
	Accrued other		899			323
	Total	$	1,875		$	798

Note_8_Property_and_Equipment_

Note 8 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]		Useful Lives			2014			2013
		(years)
	Software - internally-developed		5		$	3,054		$	2,877
	Software - purchased	3	-	5		152			596
	Computer equipment	3	-	5		613			589
	Medical equipment		5			626			-
	Furniture and fixtures		5			390			358
	Vehicles		5			43			-
	Leasehold improvements		7			2,151			205
						7,029			4,625
	Accumulated depreciation and amortization					(2,707	)		(3,389	)
	Property and equipment, net				$	4,322		$	1,236

Note_9_Goodwill_and_Intangible1

Note 9 - Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]		31-Dec-14			31-Dec-13
	Gross carrying amount of urgent and primary care intangibles:
	Patient relationships and contracts	$	972		$	-
	Accumulated amortization		(47	)		-
	Urgent and primary care intangibles, net		925			-
	Gross carrying amount of ancillary intangibles:
	Ancillary provider network		1,921			1,921
	Software		428			428
			2,349			2,349
	Accumulated amortization		(1,837	)		(1,709	)
	Other intangibles, net		512			640
	Total intangibles, net	$	1,437		$	640
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Years ending December 31,	Urgent and			Ancillary Care			Total
		Primary Care			Services
	2015	$	194		$	128		$	322
	2016		194			128			322
	2017		194			128			322
	2018		194			128			322
	2019		149			-			149
	Total	$	925		$	512		$	1,437

Note_11_Income_Taxes_Tables

Note 11 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]		2014			2013
	Computed "expected" tax provision (benefit)	$	(2,276	)	$	(1,278	)
	Increase in the valuation allowance for deferred tax assets		2,287			1,009
	Shortfall on stock options, warrants, and RSUs		215			330
	State taxes		12			19
	Permanent items		45			12
	Tax benefit recognized related to stock acquisition		(145	)		-
	Other		(68	)		(67	)
	Total income tax provision	$	70		$	25
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]		2014			2013
	Deferred tax assets:
	Operating loss carryforward	$	4,951		$	3,197
	Accounts receivable allowance		401			69
	Texas tax credit carryforward		215			221
	Stock option compensation		1,121			1,070
	Goodwill and intangibles		403			602
	Finance costs		209			-
	Accrued expenses		209			120
	Alternative Minimum Tax credit carryforwards		16			16
	Total deferred tax assets		7,525			5,295
	Deferred tax liabilities:
	Property and equipment		(518	)		(397	)
	Prepaid expense		(96	)		(71	)
	Total deferred tax liabilities		(614	)		(468	)
	Valuation allowance		(6,893	)		(4,606	)
	Net deferred tax assets	$	18		$	221
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]		2014			2013
	Current	$	12		$	18
	Deferred		58			7
		$	70		$	25

Note_12_Stockbased_Compensatio1

Note 12 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]		2014			2013
	Weighted-average grant date fair value	$	2		$	1.01
	Weighted-average assumptions used:
	Expected volatility		72.8	%		77.7	%
	Expected lives (years)		5			6.2
	Risk free interest rate		1.7	%		1	%
	Forfeiture rate		29.5	%		20.5	%
	Dividend rate		0	%		0	%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]		Options			Weighted-Average
					Exercise Price
	Outstanding at December 31, 2012		792		$	6.06
	Granted		284			1.88
	Forfeited		(113	)		2.88
	Cancelled		(208	)		6.99
	Exercised		(5	)		0.93
	Outstanding at December 31, 2013		750			4.74
	Granted		734			2.26
	Forfeited		(214	)		2.13
	Cancelled		(25	)		6.34
	Outstanding at December 31, 2014		1,245		$	3.69
	Exercisable at December 31, 2014		543		$	5.51
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable [Table Text Block]		Options Outstanding						Options Exercisable
	Range of Exercise Price	Number		Weighted-	Weighted-			Number	Weighted-
		Outstanding		Average	Average			Exercisable	Average
				Outstanding	Exercise				Exercise
				Contractual Life	Price				Price
	Under $1.00	53		0.5	$	0.93		52	$	0.93
	$1.00- $2.00	645		8.3		1.87		160		1.83
	$2.01- $3.00	87		9.54		2.81		-		-
	$3.01- $4.00	130		9.54		3.32		8		3.2
	$4.01- $5.00	25		3.49		4.24		24		4.24
	$5.01- $6.00	96		2.29		5.56		96		5.56
	$6.01- $7.00	84		2.49		6.14		78		6.14
	Greater than $7.01	125		2.16		12.08		125		12.08
		1,245		6.64	$	3.69		543	$	5.51
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]		RSUs			Weighted-Average
					Grant Date Fair Value
	Outstanding at December 31, 2012		4		$	21.4
	Granted		50			1.99
	Forfeited		(1	)		21.63
	Converted to common stock		(2	)		21.32
	Outstanding at December 31, 2013		51			2.4
	Granted		105			3.49
	Outstanding at December 31, 2014		156		$	3.08
	Vested and convertible to common stock at December 31, 2014		56		$	2.65

Note_13_Warrants_Tables

Note 13 - Warrants (Tables)	12 Months Ended
	Dec. 31, 2014
Warrants [Abstract]
Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]		31-Dec-14			30-Jul-14
	Stock price	$	2.9		$	3.14
	Volatility		72.5	%		61.5	%
	Risk-free interest rate		1.65	%		1.83	%
	Exercise price	$	3.15		$	3.15
	Expected life (years)		4.83			5.25
	Dividend yield		0	%		0	%
		31-Dec-14			4-Dec-14
	Stock price	$	2.9		$	2.71
	Volatility		72.5	%		72.5	%
	Risk-free interest rate		1.65	%		1.59	%
	Exercise price	$	2.71		$	2.71
	Expected life (years)		4.93			5
	Dividend yield		0	%		0	%
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]		Weighted-			Warrants			Warrants		Warrants
		Average			Outstanding			Issued		Outstanding
		Exercise			December 31,			in 2014		December 31,
		Price			2013					2014
	Warrants issued July 30, 2014	$	3.15			-			800		800
	Warrants issued December 4, 2014	$	2.71			-			960		960
	Total	$	2.91			-			1,760		1,760
Change in Warrant Fair Value [Table Text Block]		Warrants			Warrants			Total
		Issued on			Issued on
		30-Jul-14			4-Dec-14
	Fair value of outstanding warrants as of December 31, 2013	$	-		$	-		$	-
	Fair value of warrants issued on July 30, 2014		1,420			-			1,420
	Fair value of warrants issued on December 4, 2014		-			1,660			1,660
	Fair value of warrants issued in 2014		1,420			1,660			3,080
	Change in fair value of warrants in 2014		(10	)		130			120
	Fair value of outstanding warrants as of December 31, 2014	$	1,410		$	1,790		$	3,200

Note_17_Segment_Reporting_Tabl

Note 17 - Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]		2014												2013
		Urgent and			Ancillary			Shared			Total			Urgent and		Ancillary		Shared			Total
		Primary Care			Network			Services						Primary Care		Network		Services
	Net revenues	$	3,906		$	23,146		$	-		$	27,052		$	-	$	26,751	$	-		$	26,751
	Total segment operating income (loss)		(80	)		1,353			(5,360	)		(4,087	)		-		1,096		(3,535	)		(2,439	)
	Additional Segment Disclosures:
	Interest expense, including loan fee amortization		658			-			-			658			-		-		-			-
	Depreciation and amortization expense		222			644			-			866			-		795		-			795
	Income tax expense (benefit)		(145	)		215			-			70			-		25		-			25
	Total asset expenditures		347			429			40			816			-		315		-			315
Reconciliation of Revenue from Segments to Consolidated [Table Text Block]		2014			2013
	Total segment operating loss	$	(4,087	)	$	(2,439	)
	Less (add):
	Severance charges		108			199
	Non-recurring transaction costs		333			50
	Depreciation and amortization expense		866			795
	Non-cash stock-based compensation expense		592			299
	Other		166			-
	Operating loss		(6,152	)		(3,782	)
	Interest expense		658			-
	(Gain)/loss on disposal of assets		(108	)		5
	Interest income		(9	)		(27	)
	Loss before income taxes	$	(6,693	)	$	(3,760	)
Reconciliation of Assets from Segment to Consolidated [Table Text Block]		Urgent and			Ancillary Network			Shared Services			Consolidated
		Primary Care
	31-Dec-14	$	11,958		$	5,202		$	3,945		$	21,105
	31-Dec-13		-			4,404			6,625			11,029

Note_1_Description_of_Business1

Note 1 - Description of Business and Change in Business Focus (Details) (USD $)	8 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2014
Note 1 - Description of Business and Change in Business Focus (Details) [Line Items]
Number of Operating Segments		2
Number of Businesses Acquired	10
Percentage of Joint Venture Owned by Minority	35.00%	35.00%
Management Services, Management Fee Percentage	120.00%	120.00%
Management Service Agreement Term		3 years
Amount Less the Aggregate Sum of Net Profit Recieved from Agreement for Purchase of Network (in Dollars)		$6,500,000
Sum of Net Profit Received Since Beginning of Management Arrangement (in Dollars)		637,786
Gross Revenues from Urgent and Primary Care (in Dollars)		$40,000,000
Georgia [Member]
Note 1 - Description of Business and Change in Business Focus (Details) [Line Items]
Number of Businesses Acquired	3
Florida [Member]
Note 1 - Description of Business and Change in Business Focus (Details) [Line Items]
Number of Businesses Acquired	2
Alabama [Member]
Note 1 - Description of Business and Change in Business Focus (Details) [Line Items]
Number of Businesses Acquired	3
Virginia [Member]
Note 1 - Description of Business and Change in Business Focus (Details) [Line Items]
Number of Businesses Acquired	2

Note_2_Basis_of_Presentation_a2

Note 2 - Basis of Presentation and Significant Accounting Policies (Details) (USD $)	8 Months Ended	12 Months Ended		3 Months Ended
	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Jun. 30, 2015	Mar. 30, 2015
Note 2 - Basis of Presentation and Significant Accounting Policies (Details) [Line Items]
Number of Business Acquisition Related Transactions		5
Business Combination, Consideration Transferred		$8,486,000
Number of Businesses Acquired	10
Operating Income (Loss)		-4,087,000	-2,439,000
Increase (Decrease) to Gross Profit		-2,370,000
Gross Profit		-6,152,000	-3,782,000
Net Cash Provided by (Used in) Operating Activities		-4,034,000	-4,188,000
Proceeds from Issuance of Common Stock		2,000,000
Number of Reportable Segments		2
Advertising Expense		193,000	65,000
Capitalized Computer Software, Net	177,000	177,000	303,000
Deferred Offering Costs	225,000	225,000
Subsequent Event [Member]
Note 2 - Basis of Presentation and Significant Accounting Policies (Details) [Line Items]
Line of Credit Facility, Remaining Borrowing Capacity					4,000,000
Scenario, Forecast [Member]
Note 2 - Basis of Presentation and Significant Accounting Policies (Details) [Line Items]
Proceeds from Issuance of Common Stock				15,000,000
Net of Provider Payments [Member]
Note 2 - Basis of Presentation and Significant Accounting Policies (Details) [Line Items]
Revenues		6,900,000	7,000,000
Urgent and Primary Care [Member]
Note 2 - Basis of Presentation and Significant Accounting Policies (Details) [Line Items]
Number of Businesses Acquired		10
Operating Income (Loss)		-80,000
Shared Services [Member]
Note 2 - Basis of Presentation and Significant Accounting Policies (Details) [Line Items]
Increase (Decrease) to Operating Income		-1,825,000
Operating Income (Loss)		($5,360,000)	($3,535,000)

Note_2_Basis_of_Presentation_a3

Note 2 - Basis of Presentation and Significant Accounting Policies (Details) - Potentially Dilutive Adjustments to Weighted Average Number of Common Shares	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	1,782	22
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	1,245	750
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	100	51

Note_3_Acquisitions_Details

Note 3 - Acquisitions (Details) (USD $)	8 Months Ended	12 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	8-May-14	Aug. 29, 2014	Sep. 12, 2014	Dec. 31, 2014
Note 3 - Acquisitions (Details) [Line Items]
Number of Businesses Acquired	10
undefined	$268,000	$268,000					268,000
Deferred Tax Liabilities, Other	145,000	145,000					145,000
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount		-145,000
Business Combination, Acquisition Related Costs		333,000
Urgent and Primary Care [Member] | CorrectMed [Member]
Note 3 - Acquisitions (Details) [Line Items]
Business Acquisition, Pro Forma Revenue		3,268,000	3,654,000
Urgent and Primary Care [Member]
Note 3 - Acquisitions (Details) [Line Items]
Number of Businesses Acquired		10
Business Acquisition, Pro Forma Revenue		7,678,000	6,949,000
CorrectMed [Member]
Note 3 - Acquisitions (Details) [Line Items]
Number of Businesses Acquired				2
Business Acquisition, Pro Forma Revenue		26,414,000	30,405,000
Bay Walk-In Clinic, Inc [Member]
Note 3 - Acquisitions (Details) [Line Items]
Number of Businesses Acquired					2
Mid-South Urgent Care, Inc [Member]
Note 3 - Acquisitions (Details) [Line Items]
Number of Businesses Acquired						2
ACSH Urgent Care of Virginia [Member]
Note 3 - Acquisitions (Details) [Line Items]
Number of Businesses Acquired							2
Stat Medical Care [Member]
Note 3 - Acquisitions (Details) [Line Items]
Number of Businesses Acquired							2
undefined	$268,000	$268,000					268,000

Note_3_Acquisitions_Details_Bu

Note 3 - Acquisitions (Details) - Businesses Acquired (USD $)	8 Months Ended	12 Months Ended	0 Months Ended
	Dec. 31, 2014	Dec. 31, 2014	Sep. 12, 2014		8-May-14	Aug. 29, 2014	Oct. 31, 2014	Dec. 31, 2014
Business Acquisition [Line Items]
Number of sites acquired	10
Net Assets Acquired		$8,486,000
Including Additional Site That is Under Construction [Member] | Mid-South Urgent Care, Inc [Member]
Business Acquisition [Line Items]
Number of sites acquired			3	[1]
Net Assets Acquired			1,554,000
CorrectMed [Member]
Business Acquisition [Line Items]
Number of sites acquired					2
Net Assets Acquired		2,649,000			2,649,000
Bay Walk-In Clinic, Inc [Member]
Business Acquisition [Line Items]
Number of sites acquired						2
Net Assets Acquired		2,024,000				2,024,000
Mid-South Urgent Care, Inc [Member]
Business Acquisition [Line Items]
Number of sites acquired			2
Net Assets Acquired		1,554,000
MedHelp [Member]
Business Acquisition [Line Items]
Number of sites acquired							1
Net Assets Acquired		880,000					880,000
Stat Medical Care [Member]
Business Acquisition [Line Items]
Number of sites acquired								2
Net Assets Acquired		$1,379,000						$1,379,000
[1]	At the time of closing of this transaction, the seller had two operating centers; the third center in Springville, Alabama, was under development at time of closing.

Note_3_Acquisitions_Details_Ac

Note 3 - Acquisitions (Details) - Acquisition Purchase Price Breakdown (USD $)	12 Months Ended		0 Months Ended
	Dec. 31, 2014		8-May-14	Aug. 29, 2014	Oct. 31, 2014	Dec. 31, 2014
Business Combination, Separately Recognized Transactions [Line Items]
Cash consideration in purchase agreement*	$7,138,000	[1]
Adjustments on closing date	51,000
Cash consideration, as adjusted	7,189,000
Deferred consideration in purchase agreement	1,500,000
Adjustments for working capital	-216,000
Valuation adjustments to promissory notes	13,000
Deferred consideration, as adjusted	1,297,000
Total Purchase Price	8,486,000
CorrectMed [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Cash consideration in purchase agreement*	2,180,000	[1]
Adjustments on closing date	4,000
Cash consideration, as adjusted	2,184,000
Deferred consideration in purchase agreement	500,000
Adjustments for working capital	-46,000
Valuation adjustments to promissory notes	11,000
Deferred consideration, as adjusted	465,000
Total Purchase Price	2,649,000		2,649,000
Bay Walk-In Clinic, Inc [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Cash consideration in purchase agreement*	1,500,000	[1]
Cash consideration, as adjusted	1,500,000
Deferred consideration in purchase agreement	700,000
Adjustments for working capital	-170,000
Valuation adjustments to promissory notes	-6,000
Deferred consideration, as adjusted	524,000
Total Purchase Price	2,024,000			2,024,000
Mid-South Urgent Care, Inc [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Cash consideration in purchase agreement*	1,350,000	[1]
Adjustments on closing date	34,000
Cash consideration, as adjusted	1,384,000
Deferred consideration in purchase agreement	150,000
Adjustments for working capital	15,000
Valuation adjustments to promissory notes	5,000
Deferred consideration, as adjusted	170,000
Total Purchase Price	1,554,000
MedHelp [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Cash consideration in purchase agreement*	780,000	[1]
Adjustments on closing date	13,000
Cash consideration, as adjusted	793,000
Deferred consideration in purchase agreement	100,000
Adjustments for working capital	-15,000
Valuation adjustments to promissory notes	2,000
Deferred consideration, as adjusted	87,000
Total Purchase Price	880,000				880,000
Stat Medical Care [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Cash consideration in purchase agreement*	1,328,000	[1]
Cash consideration, as adjusted	1,328,000
Deferred consideration in purchase agreement	50,000
Valuation adjustments to promissory notes	1,000
Deferred consideration, as adjusted	51,000
Total Purchase Price	$1,379,000					$1,379,000
[1]	$268,000 was due to seller, Stat Medical Care, as of December 31, 2014.

Note_3_Acquisitions_Details_Su

Note 3 - Acquisitions (Details) - Summary of the Assets Acquired and Liabilities Assumed (USD $)	Dec. 31, 2014
Note 3 - Acquisitions (Details) - Summary of the Assets Acquired and Liabilities Assumed [Line Items]
Accounts receivable	$630,000
Other current assets	117,000
Property and equipment	2,984,000
Identifiable intangible assets	972,000
Goodwill	6,182,000
Total assets acquired	10,885,000
Liabilities assumed	-2,254,000
Deferred tax liability	-145,000
Net assets acquired	8,486,000
CorrectMed [Member]
Note 3 - Acquisitions (Details) - Summary of the Assets Acquired and Liabilities Assumed [Line Items]
Accounts receivable	221,000
Other current assets	48,000
Property and equipment	1,325,000
Identifiable intangible assets	110,000
Goodwill	1,871,000
Total assets acquired	3,575,000
Liabilities assumed	-926,000
Net assets acquired	2,649,000
Bay Walk-In Clinic, Inc [Member]
Note 3 - Acquisitions (Details) - Summary of the Assets Acquired and Liabilities Assumed [Line Items]
Accounts receivable	153,000
Property and equipment	63,000
Identifiable intangible assets	97,000
Goodwill	1,788,000
Total assets acquired	2,101,000
Liabilities assumed	-77,000
Net assets acquired	2,024,000
Mid-South Urgent Care, Inc [Member]
Note 3 - Acquisitions (Details) - Summary of the Assets Acquired and Liabilities Assumed [Line Items]
Accounts receivable	147,000
Other current assets	32,000
Property and equipment	1,205,000
Identifiable intangible assets	105,000
Goodwill	1,437,000
Total assets acquired	2,926,000
Liabilities assumed	-1,227,000
Deferred tax liability	-145,000
Net assets acquired	1,554,000
MedHelp [Member]
Note 3 - Acquisitions (Details) - Summary of the Assets Acquired and Liabilities Assumed [Line Items]
Accounts receivable	28,000
Other current assets	37,000
Property and equipment	180,000
Identifiable intangible assets	600,000
Goodwill	44,000
Total assets acquired	889,000
Liabilities assumed	-9,000
Net assets acquired	880,000
Stat Medical Care [Member]
Note 3 - Acquisitions (Details) - Summary of the Assets Acquired and Liabilities Assumed [Line Items]
Accounts receivable	81,000
Property and equipment	211,000
Identifiable intangible assets	60,000
Goodwill	1,042,000
Total assets acquired	1,394,000
Liabilities assumed	-15,000
Net assets acquired	$1,379,000

Note_3_Acquisitions_Details_Pr

Note 3 - Acquisitions (Details) - Pro Forma Financial Information for the Company (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Ancillary Network [Member] | CorrectMed [Member]
Note 3 - Acquisitions (Details) - Pro Forma Financial Information for the Company [Line Items]
Net revenues	$23,146,000	$26,751,000
Urgent and Primary Care [Member] | CorrectMed [Member]
Note 3 - Acquisitions (Details) - Pro Forma Financial Information for the Company [Line Items]
Net revenues	3,268,000	3,654,000
Urgent and Primary Care [Member]
Note 3 - Acquisitions (Details) - Pro Forma Financial Information for the Company [Line Items]
Net revenues	7,678,000	6,949,000
CorrectMed [Member]
Note 3 - Acquisitions (Details) - Pro Forma Financial Information for the Company [Line Items]
Net revenues	26,414,000	30,405,000
Net loss	($7,020,000)	($4,921,000)
Loss per basic and diluted common share (in Dollars per share)	($1.10)	($0.86)

Note_3_Acquisitions_Details_Re

Note 3 - Acquisitions (Details) - Revenue Since Acquisition (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Note 3 - Acquisitions (Details) - Revenue Since Acquisition [Line Items]
Revenue	$3,906
CorrectMed [Member]
Note 3 - Acquisitions (Details) - Revenue Since Acquisition [Line Items]
Revenue	2,144
Bay Walk-In Clinic, Inc [Member]
Note 3 - Acquisitions (Details) - Revenue Since Acquisition [Line Items]
Revenue	719
Mid-South Urgent Care, Inc [Member]
Note 3 - Acquisitions (Details) - Revenue Since Acquisition [Line Items]
Revenue	875
MedHelp [Member]
Note 3 - Acquisitions (Details) - Revenue Since Acquisition [Line Items]
Revenue	$168

Note_4_Accounts_Receivable_and2

Note 4 - Accounts Receivable and Revenue (Details) (USD $)	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Accounts Receivable And Revenue [Abstract]
Sales Allowances, Services		$60,000	$287,000
Allowance for Doubtful Accounts Receivable	300,000	300,000	336,000
Expenses Reimbursement to HealthSmart	903,000
	560,000
	$343,000	$903,000

Note_4_Accounts_Receivable_and3

Note 4 - Accounts Receivable and Revenue (Details) - Accounts Receivable from Urgent and Primary Care (USD $)	Dec. 31, 2014	Dec. 31, 2013
Accounts, Notes, Loans and Financing Receivable [Line Items]
Estimated allowance for uncollectible amounts	($300,000)	($336,000)
Urgent and Primary Care [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	2,434,000
Estimated allowance for uncollectible amounts	-847,000
Accounts receivable, net	$1,587,000

Note_4_Accounts_Receivable_and4

Note 4 - Accounts Receivable and Revenue (Details) - Revenue from Urgent and Primary Care (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenue	$27,052	$26,751
Urgent and Primary Care [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Gross revenue	7,259
Provision for contractual adjustments and estimated uncollectible amounts	-3,353
Net revenue	$3,906

Note_4_Accounts_Receivable_and5

Note 4 - Accounts Receivable and Revenue (Details) - Revenue and Receivables from Significant Clients (Customer Concentration Risk [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
HealthSmart Preferred Care II, L.P. [Member] | Ancillary Network [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Accounts Receivable	$870	$532
HealthSmart Preferred Care II, L.P. [Member] | Ancillary Network [Member] | Sales Revenue [Member]
Concentration Risk [Line Items]
Revenue	7,764	5,905
% of Total Revenue	34.00%	22.00%
HealthMarkets, Inc [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Accounts Receivable	244	252
HealthMarkets, Inc [Member] | Sales Revenue [Member]
Concentration Risk [Line Items]
Revenue	1,967	3,599
% of Total Revenue	9.00%	13.00%
Benefit Administrative Systems, LLC [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Accounts Receivable	179	148
Benefit Administrative Systems, LLC [Member] | Sales Revenue [Member]
Concentration Risk [Line Items]
Revenue	$1,818	$2,618
% of Total Revenue	8.00%	10.00%

Note_5_Capital_and_Operating_L2

Note 5 - Capital and Operating Lease Obligations (Details) - Future Required Payments under Lease Agreements (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Note 5 - Capital and Operating Lease Obligations (Details) - Future Required Payments under Lease Agreements [Line Items]
2015	$1,009
2016	1,178
2017	1,053
2018	927
2019	858
Thereafter	3,725
Total minimum lease payments	8,750
Less current obligation under capital lease	117
Long-term obligation under capital lease	1,764
Equipment [Member]
Note 5 - Capital and Operating Lease Obligations (Details) - Future Required Payments under Lease Agreements [Line Items]
2015	280
2016	299
2017	287
2018	276
2019	273
Thereafter	2,898
Total minimum lease payments	4,313
Less amount representing interest	-2,432
Present value of net minimum obligations	1,881
Less current obligation under capital lease	117
Long-term obligation under capital lease	1,764
Building [Member]
Note 5 - Capital and Operating Lease Obligations (Details) - Future Required Payments under Lease Agreements [Line Items]
2015	729
2016	879
2017	766
2018	651
2019	585
Thereafter	827
Total minimum lease payments	$4,437

Note_6_Lines_of_Credit_Promiss2

Note 6 - Lines of Credit, Promissory Notes, and Notes Payable (Details) (USD $)	12 Months Ended	0 Months Ended
	Dec. 31, 2014	Jul. 30, 2014	Dec. 04, 2014
Note 6 - Lines of Credit, Promissory Notes, and Notes Payable (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)	1,760,000
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum	2.50%
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Maximum	3.00%
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months	$989,000
Long-term Debt, Maturities, Repayments of Principal in Year Two	4,986,000
Long-term Debt, Maturities, Repayments of Principal in Year Three	28,000
Long-term Debt, Maturities, Repayments of Principal in Year Four	8,000
Long-term Debt, Maturities, Repayments of Principal in Year Five	6,000
July 30, 2014 Warrants [Member]
Note 6 - Lines of Credit, Promissory Notes, and Notes Payable (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)		800,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$3.15	3.15
December 4, 2014 Warrants [Member]
Note 6 - Lines of Credit, Promissory Notes, and Notes Payable (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)			960,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$2.71		$2.71
Revolving Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member] | Wells Fargo [Member]
Note 6 - Lines of Credit, Promissory Notes, and Notes Payable (Details) [Line Items]
Debt Instrument, Basis Spread on Variable Rate		1.75%
Revolving Credit Facility [Member] | Wells Fargo [Member]
Note 6 - Lines of Credit, Promissory Notes, and Notes Payable (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		5,000,000	6,000,000
Long-term Line of Credit	$4,716,000
Debt, Weighted Average Interest Rate	1.92%

Note_6_Lines_of_Credit_Promiss3

Note 6 - Lines of Credit, Promissory Notes, and Notes Payable (Details) - Summary of Promissory Notes (USD $)	Dec. 31, 2014		Aug. 29, 2014		8-May-14		Sep. 12, 2014		Oct. 31, 2014
In Thousands, unless otherwise specified
Note 6 - Lines of Credit, Promissory Notes, and Notes Payable (Details) - Summary of Promissory Notes [Line Items]
Amount issued	$1,297	[1]
Note Payable 1 [Member] | Bay Walk-In Clinic, Inc [Member]
Note 6 - Lines of Credit, Promissory Notes, and Notes Payable (Details) - Summary of Promissory Notes [Line Items]
Amount issued			30	[1]
Interest rate			5.00%
Note Payable 2 [Member] | Bay Walk-In Clinic, Inc [Member]
Note 6 - Lines of Credit, Promissory Notes, and Notes Payable (Details) - Summary of Promissory Notes [Line Items]
Amount issued			205	[1]
Interest rate			5.00%
CorrectMed [Member]
Note 6 - Lines of Credit, Promissory Notes, and Notes Payable (Details) - Summary of Promissory Notes [Line Items]
Amount issued					465	[1]
Interest rate					5.00%
Bay Walk-In Clinic, Inc [Member]
Note 6 - Lines of Credit, Promissory Notes, and Notes Payable (Details) - Summary of Promissory Notes [Line Items]
Amount issued			289	[1]
Interest rate
Mid-South Urgent Care, Inc [Member]
Note 6 - Lines of Credit, Promissory Notes, and Notes Payable (Details) - Summary of Promissory Notes [Line Items]
Amount issued							170	[1],[2]
Interest rate							5.00%
MedHelp [Member]
Note 6 - Lines of Credit, Promissory Notes, and Notes Payable (Details) - Summary of Promissory Notes [Line Items]
Amount issued									87	[1],[2]
Interest rate									5.00%
Stat Medical Care [Member]
Note 6 - Lines of Credit, Promissory Notes, and Notes Payable (Details) - Summary of Promissory Notes [Line Items]
Amount issued	$51	[1],[2]
Interest rate	5.00%
[1]	Amounts include working capital and valuation adjustments
[2]	Promissory notes issued to seller physicians are related parties. See Note 16 - Related Party Transactions.

Note_6_Lines_of_Credit_Promiss4

Note 6 - Lines of Credit, Promissory Notes, and Notes Payable (Details) - Summary of All Debt (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Note 6 - Lines of Credit, Promissory Notes, and Notes Payable (Details) - Summary of All Debt [Line Items]
Short-term and long-term debt	$6,017
Less current maturities	989
Long-term debt	5,028
Revolving Line of Credit [Member]
Note 6 - Lines of Credit, Promissory Notes, and Notes Payable (Details) - Summary of All Debt [Line Items]
Short-term and long-term debt	4,716
Promissory Notes, Related to Acquistion [Member]
Note 6 - Lines of Credit, Promissory Notes, and Notes Payable (Details) - Summary of All Debt [Line Items]
Short-term and long-term debt	1,263
Note Payable 1 [Member]
Note 6 - Lines of Credit, Promissory Notes, and Notes Payable (Details) - Summary of All Debt [Line Items]
Short-term and long-term debt	$38

Note_7_Accrued_Liabilities_Det

Note 7 - Accrued Liabilities (Details) - Accrued Liabilities (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Liabilities [Abstract]
Purchase price due to seller, Stat Medical	$268
Accrued management fees	218	173
Personnel-related	344	122
Professional fees	146	180
Accrued other	899	323
Total	$1,875	$798

Note_8_Property_and_Equipment_1

Note 8 - Property and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Depreciation	$691,000	$667,000
Capitalized Computer Software, Amortization	$432,000	$503,000

Note_8_Property_and_Equipment_2

Note 8 - Property and Equipment (Details) - Property and Equipment (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$7,029	$4,625
Accumulated depreciation and amortization	-2,707	-3,389
Property and equipment, net	4,322	1,236
Software Internally Developed [Member]
Property, Plant and Equipment [Line Items]
Useful lives	5 years
Property and equipment, gross	3,054	2,877
Purchased Software [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful lives	3 years
Purchased Software [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful lives	5 years
Purchased Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	152	596
Computer Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful lives	3 years
Computer Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful lives	5 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	613	589
Medical Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful lives	5 years
Property and equipment, gross	626
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Useful lives	5 years
Property and equipment, gross	390	358
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Useful lives	5 years
Property and equipment, gross	43
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Useful lives	7 years
Property and equipment, gross	$2,151	$205

Note_9_Goodwill_and_Intangible2

Note 9 - Goodwill and Intangible Assets (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Goodwill	$6,182,000
Amortization of Intangible Assets	$175,000	$128,000
Patient Base [Member]
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	5 years
Ancillary Provider Network [Member]
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	15 years
Minimum [Member]
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Finite Lived Intangible Assets, Rate of Attrition	2.00%
Maximum [Member]
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Finite Lived Intangible Assets, Rate of Attrition	8.00%

Note_9_Goodwill_and_Intangible3

Note 9 - Goodwill and Intangible Assets (Details) - Other Intangible Assets and Related Accumulated Amortization (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]
Intangible assets, net	$1,437	$640
Urgent and Primary Care [Member] | Patient Relationships and Contracts [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	972
Urgent and Primary Care [Member]
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	-47
Intangible assets, net	925
Ancillary Network [Member] | Ancillary Provider Network [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	1,921	1,921
Ancillary Network [Member] | Software Internally Developed [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	428	428
Ancillary Network [Member] | Computer Software, Intangible Asset [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	2,349	2,349
Ancillary Network [Member]
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	-1,837	-1,709
Intangible assets, net	$512	$640

Note_9_Goodwill_and_Intangible4

Note 9 - Goodwill and Intangible Assets (Details) - Finite-lived Intangible Assets Future Amortization Expense (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Note 9 - Goodwill and Intangible Assets (Details) - Finite-lived Intangible Assets Future Amortization Expense [Line Items]
2015	$322
2016	322
2017	322
2018	322
2019	149
Total	1,437	640
Urgent and Primary Care [Member]
Note 9 - Goodwill and Intangible Assets (Details) - Finite-lived Intangible Assets Future Amortization Expense [Line Items]
2015	194
2016	194
2017	194
2018	194
2019	149
Total	925
Ancillary Care Services [Member]
Note 9 - Goodwill and Intangible Assets (Details) - Finite-lived Intangible Assets Future Amortization Expense [Line Items]
2015	128
2016	128
2017	128
2018	128
Total	$512

Note_10_Private_PlacementEquit1

Note 10 - Private Placement/Equity (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	5-May-14
Note 10 - Private Placement/Equity (Details) [Line Items]
Common Stock, Shares, Issued	6,713,000	5,713,000
Common Stock, Value, Issued	$67,000	$57,000
Private Placement [Member]
Note 10 - Private Placement/Equity (Details) [Line Items]
Common Stock, Shares, Issued			1,000,000
Share Price			$2
Common Stock, Value, Issued			$2,000,000

Note_11_Income_Taxes_Details

Note 11 - Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Note 11 - Income Taxes (Details) [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	$2,287,000	$1,009,000
Texas Tax Credit Carryforward	18,000
Operating Loss Carryforwards	19,600,000	14,500,000
Deferred Tax Assets, Net of Valuation Allowance	18,000	221,000
Expected Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation	1,900,000
Excess Tax Benefits on Stock Options and Warrants Exercised [Member]
Note 11 - Income Taxes (Details) [Line Items]
Deferred Tax Assets, Net of Valuation Allowance	$5,400,000

Note_11_Income_Taxes_Details_E

Note 11 - Income Taxes (Details) - Effective Income Tax Rate Reconciliation (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Effective Income Tax Rate Reconciliation [Abstract]
Computed "expected" tax provision (benefit)	($2,276,000)	($1,278,000)
Increase in the valuation allowance for deferred tax assets	2,287,000	1,009,000
Shortfall on stock options, warrants, and RSUs	215,000	330,000
State taxes	12,000	19,000
Permanent items	45,000	12,000
Tax benefit recognized related to stock acquisition	-145,000
Other	-68,000	-67,000
Total income tax provision	$70,000	$25,000

Note_11_Income_Taxes_Details_D

Note 11 - Income Taxes (Details) - Deferred Tax Assets and Liabilities (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred tax assets:
Operating loss carryforward	$4,951	$3,197
Accounts receivable allowance	401	69
Texas tax credit carryforward	215	221
Stock option compensation	1,121	1,070
Goodwill and intangibles	403	602
Finance costs	209
Accrued expenses	209	120
Alternative Minimum Tax credit carryforwards	16	16
Total deferred tax assets	7,525	5,295
Deferred tax liabilities:
Property and equipment	-518	-397
Prepaid expense	-96	-71
Total deferred tax liabilities	-614	-468
Valuation allowance	-6,893	-4,606
Net deferred tax assets	$18	$221

Note_11_Income_Taxes_Details_C

Note 11 - Income Taxes (Details) - Components of Income Tax Expense (Benefit) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Components of Income Tax Expense (Benefit) [Abstract]
Current	$12	$18
Deferred	58	7
	$70	$25

Note_12_Stockbased_Compensatio2

Note 12 - Stock-based Compensation (Details) (USD $)	12 Months Ended		72 Months Ended	0 Months Ended	116 Months Ended	0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	16-May-05	Dec. 31, 2014	Jun. 03, 2014	19-May-09	Dec. 31, 2012
Note 12 - Stock-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	734,000	284,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,245,000	750,000	1,245,000		1,245,000			792,000
Allocated Share-based Compensation Expense	$592,000	$299,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	6 years 219 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	3 years 73 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	774,000	46,000	774,000		774,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	274,000	40,000	274,000		274,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	308	5,411
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	390	5,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	894,000		894,000		894,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	4 years 36 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate	29.50%	20.50%
Restricted Stock Units Issued in Violation of Terms of Share-based Compensation Plans, Amount			100,660
Restricted Stock Units (RSUs) [Member] | Management [Member]
Note 12 - Stock-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	55,000
Restricted Stock Units (RSUs) [Member]
Note 12 - Stock-based Compensation (Details) [Line Items]
Allocated Share-based Compensation Expense	208,000	52,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 6 months
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate	5.00%
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	50,000	50,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	219,000		219,000		219,000
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number	155,663		155,663		155,663
Non-qualified Stock Option [Member]
Note 12 - Stock-based Compensation (Details) [Line Items]
Allocated Share-based Compensation Expense	$384,000	$247,000
Stock Option Plan [Member]
Note 12 - Stock-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				749,776
Share-based Goods and Nonemployee Services Transaction, Shares Approved for Issuance				16,667
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized					1,249,776
The 2009 Plan [Member]
Note 12 - Stock-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period							10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized						2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized							500,000
Stock Option Plan and the 2009 Plan [Member]
Note 12 - Stock-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,381,914	482,083	1,381,914		1,381,914

Note_12_Stockbased_Compensatio3

Note 12 - Stock-based Compensation (Details) - Valuation Assumptions (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Valuation Assumptions [Abstract]
Weighted-average grant date fair value (in Dollars per share)	$2	$1.01
Weighted-average assumptions used:
Expected volatility	72.80%	77.70%
Expected lives (years)	5 years	6 years 73 days
Risk free interest rate	1.70%	1.00%
Forfeiture rate	29.50%	20.50%
Dividend rate	0.00%	0.00%

Note_12_Stockbased_Compensatio4

Note 12 - Stock-based Compensation (Details) - Stock Option Activity (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Stock Option Activity [Abstract]
Outstanding	750,000	792,000
Outstanding	$4.74	$6.06
Exercisable at December 31, 2014	543,000
Exercisable at December 31, 2014	$5.51
Granted	734,000	284,000
Granted	$2.26	$1.88
Forfeited	-214,000	-113,000
Forfeited	$2.13	$2.88
Cancelled	-25,000	-208,000
Cancelled	$6.34	$6.99
Exercised	-308	-5,411
Exercised		$0.93
Outstanding	1,245,000	750,000
Outstanding	$3.69	$4.74

Note_12_Stockbased_Compensatio5

Note 12 - Stock-based Compensation (Details) - Summaries of Outstanding and Exercisable Options (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014
Note 12 - Stock-based Compensation (Details) - Summaries of Outstanding and Exercisable Options [Line Items]
Number of outstanding options (in Shares)	1,245
Outstanding options, weighted average outstanding contractual term	6 years 233 days
Outstanding options, weighted average exercise price	$3.69
Number of exerciasbale options (in Shares)	543
Exercisable options, weighted average exercise price	$5.51
Exercise Price Range, Group 1 [Member]
Note 12 - Stock-based Compensation (Details) - Summaries of Outstanding and Exercisable Options [Line Items]
Exercise Price range, upper range limit	$1
Number of outstanding options (in Shares)	53
Outstanding options, weighted average outstanding contractual term	6 months
Outstanding options, weighted average exercise price	$0.93
Number of exerciasbale options (in Shares)	52
Exercisable options, weighted average exercise price	$0.93
Exercise Price Range, Group 2 [Member]
Note 12 - Stock-based Compensation (Details) - Summaries of Outstanding and Exercisable Options [Line Items]
Exercise price range, lower range limit	$1
Exercise Price range, upper range limit	$2
Number of outstanding options (in Shares)	645
Outstanding options, weighted average outstanding contractual term	8 years 109 days
Outstanding options, weighted average exercise price	$1.87
Number of exerciasbale options (in Shares)	160
Exercisable options, weighted average exercise price	$1.83
Exercise Price Range, Group 3 [Member]
Note 12 - Stock-based Compensation (Details) - Summaries of Outstanding and Exercisable Options [Line Items]
Exercise price range, lower range limit	$2.01
Exercise Price range, upper range limit	$3
Number of outstanding options (in Shares)	87
Outstanding options, weighted average outstanding contractual term	9 years 197 days
Outstanding options, weighted average exercise price	$2.81
Exercise Price Range, Group 4 [Member]
Note 12 - Stock-based Compensation (Details) - Summaries of Outstanding and Exercisable Options [Line Items]
Exercise price range, lower range limit	$3.01
Exercise Price range, upper range limit	$4
Number of outstanding options (in Shares)	130
Outstanding options, weighted average outstanding contractual term	9 years 197 days
Outstanding options, weighted average exercise price	$3.32
Number of exerciasbale options (in Shares)	8
Exercisable options, weighted average exercise price	$3.20
Exercise Price Range, Group 5 [Member]
Note 12 - Stock-based Compensation (Details) - Summaries of Outstanding and Exercisable Options [Line Items]
Exercise price range, lower range limit	$4.01
Exercise Price range, upper range limit	$5
Number of outstanding options (in Shares)	25
Outstanding options, weighted average outstanding contractual term	3 years 178 days
Outstanding options, weighted average exercise price	$4.24
Number of exerciasbale options (in Shares)	24
Exercisable options, weighted average exercise price	$4.24
Exercise Price Range, Group 6 [Member]
Note 12 - Stock-based Compensation (Details) - Summaries of Outstanding and Exercisable Options [Line Items]
Exercise price range, lower range limit	$5.01
Exercise Price range, upper range limit	$6
Number of outstanding options (in Shares)	96
Outstanding options, weighted average outstanding contractual term	2 years 105 days
Outstanding options, weighted average exercise price	$5.56
Number of exerciasbale options (in Shares)	96
Exercisable options, weighted average exercise price	$5.56
Exercise Price Range, Group 7 [Member]
Note 12 - Stock-based Compensation (Details) - Summaries of Outstanding and Exercisable Options [Line Items]
Exercise price range, lower range limit	$6.01
Exercise Price range, upper range limit	$7
Number of outstanding options (in Shares)	84
Outstanding options, weighted average outstanding contractual term	2 years 178 days
Outstanding options, weighted average exercise price	$6.14
Number of exerciasbale options (in Shares)	78
Exercisable options, weighted average exercise price	$6.14
Exercise Price Range, Group 8 [Member]
Note 12 - Stock-based Compensation (Details) - Summaries of Outstanding and Exercisable Options [Line Items]
Exercise price range, lower range limit	$7.01
Number of outstanding options (in Shares)	125
Outstanding options, weighted average outstanding contractual term	2 years 58 days
Outstanding options, weighted average exercise price	$12.08
Number of exerciasbale options (in Shares)	125
Exercisable options, weighted average exercise price	$12.08

Note_12_Stockbased_Compensatio6

Note 12 - Stock-based Compensation (Details) - Summary of Restricted Stock Options Activity (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Note 12 - Stock-based Compensation (Details) - Summary of Restricted Stock Options Activity [Line Items]
Forfeited	214,000	113,000
Restricted Stock Units (RSUs) [Member] | Includes Units Awarded to Non-senior Management and Senior Management [Member]
Note 12 - Stock-based Compensation (Details) - Summary of Restricted Stock Options Activity [Line Items]
Equity instruments other than options, number of shares granted	105,000	50,000
Equity instruments other than options, weighted average grant date fair value granted	3.49	1.99
Restricted Stock Units (RSUs) [Member]
Note 12 - Stock-based Compensation (Details) - Summary of Restricted Stock Options Activity [Line Items]
Equity instruments other than options, number of shares outstanding	51,000	4,000
Equity instruments other than options, weighted average grant date fair value outstanding	2.4	21.4
Vested and convertible to common stock at December 31, 2014	56,000
Vested and convertible to common stock at December 31, 2014	2.65
Equity instruments other than options, number of shares granted	50,000	50,000
Forfeited		-1,000
Forfeited		21.63
Converted to common stock		-2,000
Converted to common stock		21.32
Equity instruments other than options, number of shares outstanding	156,000	51,000
Equity instruments other than options, weighted average grant date fair value outstanding	3.08	2.4

Note_13_Warrants_Details

Note 13 - Warrants (Details) (USD $)	12 Months Ended	0 Months Ended	5 Months Ended	0 Months Ended
	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 04, 2014	Dec. 31, 2013	Jul. 30, 2014
Note 13 - Warrants (Details) [Line Items]
Class of Warrant or Right, Outstanding (in Shares)	1,782,222	1,782,222	1,782,222		22,222
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)	1,760,000	1,760,000	1,760,000
Fair Value Adjustment of Warrants	$120
Warrant [Member]
Note 13 - Warrants (Details) [Line Items]
Class of Warrant or Right, Outstanding (in Shares)	1,760,000	1,760,000	1,760,000
Warrant [Member]
Note 13 - Warrants (Details) [Line Items]
Class of Warrant or Right, Outstanding (in Shares)	22,222	22,222	22,222		22,222
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)					1.5
July 30, 2014 Warrants [Member]
Note 13 - Warrants (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$3.15	$3.15	$3.15			$3.15
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)						800,000
Difference In Warrant Exercise Price And Market Price Per Share (in Dollars per share)						$0.01
Warrant Liability Based on Warrants' Fair Value						1,420,000
Amortization of Financing Costs	322,000
Fair Value Adjustment of Warrants	-10	1,410,000
Unrealized Gain on Securities			10,000
Probability of Future Private Stock Offering	15.00%
December 4, 2014 Warrants [Member]
Note 13 - Warrants (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$2.71	$2.71	$2.71	$2.71
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)				960,000
Warrant Liability Based on Warrants' Fair Value				1,660,000
Amortization of Financing Costs	92,000
Fair Value Adjustment of Warrants	130	1,790,000
Unrealized Gain on Securities				-130,000
Probability of Future Private Stock Offering	100.00%
Revolving Credit Facility [Member] | Wells Fargo [Member]
Note 13 - Warrants (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity				$6,000,000		$5,000,000

Note_13_Warrants_Details_Assum

Note 13 - Warrants (Details) - Assumptions Used for Warrants Issued (USD $)	7 Months Ended	12 Months Ended	11 Months Ended
	Jul. 30, 2014	Dec. 31, 2014	Dec. 04, 2014
July 30, 2014 Warrants [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Stock price (in Dollars per share)	$3.14	$2.90
Volatility	61.50%	72.50%
Risk-free interest rate	1.83%	1.65%
Exercise price (in Dollars per share)	$3.15	$3.15
Expected life (years)	5 years 3 months	4 years 302 days
Dividend yield	0.00%	0.00%
December 4, 2014 Warrants [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Stock price (in Dollars per share)		$2.90	$2.71
Volatility		72.50%	72.50%
Risk-free interest rate		1.65%	1.59%
Exercise price (in Dollars per share)		$2.71	$2.71
Expected life (years)		4 years 339 days	5 years
Dividend yield		0.00%	0.00%

Note_13_Warrants_Details_The_C

Note 13 - Warrants (Details) - The Company Warrants' Anti-dilution (USD $)	12 Months Ended	0 Months Ended
	Dec. 31, 2014	Jul. 30, 2014	Dec. 04, 2014
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	$2.91
Warrants Outstanding	1,760,000
Warrants Issued	1,760,000
July 30, 2014 Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)		$3.15
Warrants Outstanding		800,000
Warrants Issued		800,000
December 4, 2014 Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)			$2.71
Warrants Outstanding			960,000
Warrants Issued			960,000

Note_13_Warrants_Details_The_C1

Note 13 - Warrants (Details) - The Changes in the Warrants' Fair Values (USD $)	0 Months Ended		12 Months Ended	0 Months Ended
	Dec. 04, 2014	Jul. 30, 2014	Dec. 31, 2014	Dec. 31, 2014
Note 13 - Warrants (Details) - The Changes in the Warrants' Fair Values [Line Items]
Fair value of outstanding warrants			$3,200	$3,200
Fair value of warrants issued	1,660	1,420	3,080
Change in fair value of warrants in 2014			120
July 30, 2014 Warrants [Member]
Note 13 - Warrants (Details) - The Changes in the Warrants' Fair Values [Line Items]
Fair value of outstanding warrants			1,410	1,410
Fair value of warrants issued		1,420	1,420
Change in fair value of warrants in 2014			-10	1,410,000
December 4, 2014 Warrants [Member]
Note 13 - Warrants (Details) - The Changes in the Warrants' Fair Values [Line Items]
Fair value of outstanding warrants			1,790	1,790
Fair value of warrants issued	1,660		1,660
Change in fair value of warrants in 2014			$130	$1,790,000

Note_15_Employee_Benefit_Plans1

Note 15 - Employee Benefit Plans (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Significant Agreements [Abstract]
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	100.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	3.50%
Defined Contribution Plan, Cost Recognized	$109,000	$98,000

Note_16_Related_Party_Transact1

Note 16 - Related Party Transactions (Details) (USD $)	0 Months Ended
	Jan. 10, 2014
Related Party Transactions [Abstract]
Related Party Monthly Fee Payable	$10,000

Note_17_Segment_Reporting_Deta

Note 17 - Segment Reporting (Details) - Consolidating Statements of Operations by Industry (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Net revenues	$27,052,000	$26,751,000
Total segment operating income (loss)	-4,087,000	-2,439,000
Additional Segment Disclosures:
Interest expense, including loan fee amortization	658,000
Depreciation and amortization expense	866,000	795,000
Income tax expense (benefit)	70,000	25,000
Total asset expenditures	816,000	315,000
Urgent and Primary Care [Member]
Segment Reporting Information [Line Items]
Net revenues	3,906,000
Total segment operating income (loss)	-80,000
Additional Segment Disclosures:
Interest expense, including loan fee amortization	658,000
Depreciation and amortization expense	222,000
Income tax expense (benefit)	-145,000
Total asset expenditures	347,000
Ancillary Network [Member]
Segment Reporting Information [Line Items]
Net revenues	23,146,000	26,751,000
Total segment operating income (loss)	1,353,000	1,096,000
Additional Segment Disclosures:
Depreciation and amortization expense	644,000	795,000
Income tax expense (benefit)	215,000	25,000
Total asset expenditures	429,000	315,000
Shared Services [Member]
Segment Reporting Information [Line Items]
Total segment operating income (loss)	-5,360,000	-3,535,000
Additional Segment Disclosures:
Total asset expenditures	$40,000

Note_17_Segment_Reporting_Deta1

Note 17 - Segment Reporting (Details) - Reconciliation of Reportable Segment Operating Income (Loss) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Reconciliation of Reportable Segment Operating Income (Loss) [Abstract]
Total segment operating loss	($4,087,000)	($2,439,000)
Less (add):
Severance charges	108,000	199,000
Non-recurring transaction costs	333,000	50,000
Depreciation and amortization expense	866,000	795,000
Non-cash stock-based compensation expense	592,000	299,000
Other	166,000
Operating loss	-6,152,000	-3,782,000
Interest expense	658,000
(Gain)/loss on disposal of assets	-108,000	5,000
Interest income	-9,000	-27,000
Loss before income taxes	($6,693,000)	($3,760,000)

Note_17_Segment_Reporting_Deta2

Note 17 - Segment Reporting (Details) - Consolidating Assets, by Segment (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	$21,105	$11,029
Urgent and Primary Care [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	11,958
Ancillary Network [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	5,202	4,404
Shared Services [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	$3,945	$6,625